



Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002856
Article Type:	Research
Date Submitted by the Author:	08-Mar-2013
Complete List of Authors:	Duarte, Rui; Birmingham City University, Faculty of Health; Russells Hall Hospital, Department of Pain Management Raphael, Jon; Birmingham City University, Faculty of Health; Russells Hall Hospital, Department of Pain Management Southall, Jane; Russells Hall Hospital, Department of Pain Management Labib, Mourad; Russells Hall Hospital, Department of Clinical Biochemistry Whallett, Andrew; Russells Hall Hospital, Department of Rheumatology Ashford, Robert; Birmingham City University, Faculty of Health
Primary Subject Heading:	Anaesthesia
Secondary Subject Heading:	Neurology
Keywords:	chronic pain, hypogonadism, drug delivery systems, implantable, bone density

SCHOLARONE™
Manuscripts

1
2
3 **Hypogonadism and low bone mineral density in patients on long-term intrathecal**
4 **opioid delivery therapy**

5
6 Rui V. Duarte,^{1,2} Jon H. Raphael,^{1,2} Jane L. Southall,² Mourad H. Labib,³ Andrew J.
7 Whallett,⁴ Robert L. Ashford¹

8
9 ¹ Faculty of Health, Birmingham City University, Birmingham, UK

10 ² Department of Pain Management, Russells Hall Hospital, Dudley, UK

11 ³ Department of Clinical Biochemistry, Russells Hall Hospital, Dudley, UK

12 ⁴ Department of Rheumatology, Russells Hall Hospital, Dudley, UK
13
14
15
16
17

18 Name and address for correspondence: Rui V. Duarte, Faculty of Health, Birmingham City
19 University, City South Campus, Room 220 Ravensbury House, B15 3TN, Birmingham,
20 United Kingdom
21
22

23
24 Tel.: +44 24768 88063; Fax: +44 0121 331 6076; Email: ruivduarte@gmail.com
25
26
27

28 Keywords: bone density; chronic pain; hypogonadism; drug delivery systems, implantable
29

30 Word count: 2,675
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives

This study aimed to investigate the hypothalamic-pituitary-gonadal axis in a sample of male patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain and the presence of osteopenia and/or osteoporosis in those diagnosed with hypogonadism.

Design

Observational study using health data routinely collected for non-research purposes.

Setting

Department of Pain Management, Russells Hall Hospital, Dudley, United Kingdom.

Patients

Twenty consecutive male patients attending follow-up clinics for intrathecal opioid therapy had the gonadal axis evaluated by measuring their serum luteinising hormone, follicle stimulating hormone, total testosterone, sex hormone binding globulin and calculation of free testosterone. Bone mineral density was measured by DEXA scanning in those patients diagnosed with hypogonadism.

Results

Based on calculated free testosterone concentrations, 17 (85%) patients had biochemical hypogonadism with 15 patients (75%) having free testosterone <180 pmol/L and 2 patients (10%) between 180 and 250 pmol/L. Bone mineral density was assessed in 14 of the 17 patients after the exclusion of 3 patients. Osteoporosis (defined as a T-score \leq -2.5 SD) was detected in three patients (21.4%) and osteopenia (defined as a T-score between -1.0 and -2.5 SD) was observed in seven patients (50%). Five of the 14 patients (35.7%) were at or above the intervention threshold for hip fracture.

Conclusion

This study suggests an association between hypogonadism and low bone mass density in patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain. Surveillance of hypogonadism and bone mineral density levels followed by appropriate treatment may be paramount to reduce the risk of osteoporosis development and prevention of fractures in this group of patients.

INTRODUCTION

Treatment strategies for the management of chronic pain start with the lowest risk and least invasive intervention and progress if a treatment is not effective. Intrathecal drug delivery

1
2
3 (IDD) is considered a last resort treatment for the management of severe chronic pain due to
4 its invasive nature, concerns about long-term opioid use, and the possible complications
5 related to this modality of treatment. Intrathecal spinal analgesia has become a recognized
6 treatment for chronic non-malignant pain since the first reservoir was implanted in 1981.[1]
7
8 The use of opioids via intrathecal drug delivery allows for a selective concentration to reach
9 an important site of pain transmission, the spinal cord dorsal horn.[2] Opioid administration
10 into the intrathecal space achieves its effects at lower doses than using the epidural route.[3]
11
12 The drug is highly localized, so its analgesic efficacy is maximized at lower doses.[4]
13
14 Moreover, opioid dose escalation throughout the years may be modest.[5,6] These factors
15 lead to a decrease in the possible opioid side-effects.
16
17
18
19
20
21
22
23
24

25 The potential effect of intrathecal opioid delivery on the endocrine system is one of the least
26 recognised and investigated.[7] Currently, opioid-induced hypogonadism is under-
27 recognised and undertreated.[8,9] Some patients may attribute the signs and symptoms of
28 hypogonadism; such as decreased libido, tiredness, loss of muscle mass and strength,
29 among others, to the chronic pain and its related conditions rather than to the intrathecal
30 medication.[7, 10] Moreover, symptoms of hypogonadism are often neither disclosed by the
31 patient nor documented by the physician.[11] The current limited clinical awareness of the
32 opioid effects on the endocrine system, together with the lack of information on their long-
33 term consequences, is likely to result in a lack of information provision to the patient when
34 long-term opioid therapy is being considered.[12]
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Animal studies suggest that opioids affect gonadotropin release via the inhibition of the
49 gonadotropin releasing hormone (GnRH) by β -endorphin,[13] most likely at μ -receptors.[14]
50 This inhibition reduces the release of luteinizing hormone (LH) and follicle stimulating
51 hormone (FSH) by the pituitary gland and consequently the production of testosterone by the
52 gonads, resulting in hypogonadism and loss of libido. This is characterized by low or low-
53
54
55
56
57
58
59
60

1
2
3 normal LH and FSH levels, and low testosterone levels.[11] Most circulating testosterone is
4 bound to sex hormone-binding globulin (SHBG). A lesser fraction is non-specifically bound to
5 albumin and only a small percentage of testosterone is unbound.[15] Historically, free
6 testosterone was thought to be the only biologically-active component. However,
7 testosterone is weakly bound to serum albumin and dissociates freely in the capillary bed,
8 and is readily available for tissue uptake. All non-SHBG-bound testosterone is therefore
9 considered bioavailable.
10

11 Hypogonadism is an important risk factor for development of osteoporosis in both sexes, but
12 opioids have not been considered as a risk factor.[16] To our knowledge, the assessment of
13 BMD in patients undertaking intrathecal drug delivery is limited to one study which
14 suggested a tendency towards decreased BMD in these patients but the prevalence of
15 osteopenia or osteoporosis in these patients was not reported in this study.[17]
16
17

18 The aim of this study was to investigate the hypothalamic-pituitary-gonadal axis in a sample
19 of male patients undertaking intrathecal opioid delivery for the management of chronic non-
20 malignant pain and to assess the prevalence of osteopenia and/or osteoporosis in those
21 diagnosed with hypogonadism.
22
23

24 **METHODS**

25 **Patients**

26 Twenty consecutive male patients attending follow-up clinics for IDD therapy at Russells Hall
27 Hospital, Dudley, UK, for the management of chronic non-cancer pain were included in this
28 observational study using health data routinely collected for non-research purposes. Patients
29 who had received testosterone supplementation within the previous three months were
30 excluded. The pain syndrome experienced by the patients was classified as nociceptive
31 (58.8%), neuropathic (5.8%) and mixed nociceptive-neuropathic (35.3%). All the patients
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 were receiving intrathecal opioids for the management of their pain. Intrathecal morphine
4 was the only medication administered to 50% of the sample. In individual cases, other
5 substances were added to the intrathecal medication, with combinations of morphine with
6 bupivacaine (12.5%), morphine with bupivacaine and clonidine (25%), and morphine with
7 bupivacaine and baclofen (12.5%).
8
9
10
11
12

13 14 15 **Laboratory Methods**

16
17 Blood samples were collected during a seven-month period (April to October 2010), as part
18 of routine clinical care, for the measurement of serum LH, FSH, total testosterone (TT) and
19 SHBG. All assays were carried out by the Department of Clinical Biochemistry at Russells
20 Hall Hospital, Dudley, UK. LH, FSH and testosterone (TT) were measured according to the
21 manufacturer's instructions by immuno-enzymometric fluorimetric assay on the Tosoh AIA
22 2000 LA analyser (Tosoh Bioscience N.V., Tessenderlo, Belgium). The inter-assay
23 imprecision (%CV) quoted by the manufacturer was 2.6% for LH, 2.3% for FSH and 5.3% for
24 testosterone. SHBG was measured according to the manufacturer's instructions by
25 chemiluminescent immunometric assay on the Immulite 2000 XPI analyser (Siemens
26 Healthcare Diagnostics Ltd, Camberley, Surrey, UK). The inter-assay variability (%CV) for
27 SHBG was 5%. Calculations of free testosterone (FT) were carried out using the Vermeulen
28 equation.[15] The quoted reference ranges were: LH (2.2-13.3 IU/L), FSH (1-7 IU/L), SHBG
29 (13-71 nmol/L) and TT (\geq 12 nmol/L). A FT < 180 picomoles per liter (pmol/L) was
30 considered as biochemical hypogonadism and FT 180-250 pmol/L as borderline/low.[18]
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **Assessment of Bone Mineral Density**

49 Bone mineral density was measured by DEXA scanning of the femur (neck and hip) and
50 lumbar spine or left forearm using the Lunar Prodigy DEXA (GE Lunar Corp., Madison, WI,
51 USA). Bone densitometry DEXA scans were carried out by the Department of Radiology, at
52 Corbett Hospital, Dudley, UK. Lumbar spine scan was not carried out in patients who had
53
54
55
56
57
58
59
60

1
2
3 previous spinal surgery. In those cases, assessment was performed at the left forearm site.
4
5 Results are presented as BMD (g/cm^2), T-scores and Z-scores. Reference values for T-
6
7 score were based on UK (ages 20-40) femur, spine or forearm reference population (v107).
8
9 Osteopenia was defined as a T-score between -1.0 and -2.5 SD, and osteoporosis as a T-
10
11 score at or below -2.5 SD. Measurements of height, weight and body mass index (BMI) were
12
13 also performed. The BMI scores were categorised according to the World Health
14
15 Organisation key cut-off points as <18.5 (underweight), ≥ 18.5 and ≤ 24.9 (normal weight), \geq
16
17 25 and ≤ 29.9 (overweight), and $\geq 30 \text{ kg}/\text{m}^2$ (obese). The 10-year probability of fracture was
18
19 calculated based on the Fracture Risk Assessment Tool (FRAX).[19] In addition to the BMD
20
21 value or T-score (femoral neck), this tool takes into account clinical risk factors for the
22
23 development of osteoporotic or hip fractures such as previous fractures, history of hip
24
25 fracture in the patient's parents and hypogonadism, among other factors.
26
27
28

29 **Data analysis**

30
31 Kolmogorov-Smirnov test was performed to test distribution of numerical data, followed by
32
33 the appropriate statistical tests. Comparisons between groups were carried out with the
34
35 Mann-Whitney test. Data is reported as median (minimum-maximum). The 95% confidence
36
37 intervals for the TT and FT median values were calculated for comparison with normal
38
39 reference values. Statistical significance was judged at 5% level. Statistical tests were
40
41 performed using Predictive Analytics SoftWare (PASW) (version 18.0, SPSS Inc., Chicago,
42
43 IL, USA).
44
45
46
47

48 **RESULTS**

49 **Assessment of Sex Hormones**

50
51 The median age at the time of blood collection was 58 years (47-69). The median duration
52
53 from implantation of the IDD system to hormone assay was 100 months (15-203) with an
54
55 intrathecal opioid dose of 2.68 mg/day (range 1-9.7) (Table 1). The duration of pain prior to
56
57
58
59
60

commencement of IDD was 9 years (range 3-35).

Table 1. Sample characteristics

Patients (N)	20
Age (years)	58 (47-69)
IDDS duration (months)	100 (15-203)
Opioid dose (mg/day)	2.68 (1-9.7)
LH (IU/L)	1.9 (0.2-19.9)
FSH (IU/L)	5.3 (0.3-23.9)
SHBG (nmol/L)	51 (17-123)
TT (nmol/L)	4.95 (1.2-18.8)
FT (pmol/L)	69.45 (14-328)

Key: LH - luteinizing hormone; FSH - follicle stimulating hormone; SHBG - sex hormone binding globulin; TT – total testosterone; FT - free testosterone

Statistics are presented as median (minimum-maximum)

The median TT levels with 95% confidence intervals was 4.95 nmol/L (3.0-10.1), which were significantly lower than the cut-off level of 12 nmol/L for borderline/low testosterone. The median FT levels with 95% confidence intervals [69.45 (47.3-127.0)] were also significantly lower than the cut-off level of 180 pmol/L for low FT ($t = -3.403$, $p < 0.005$, $r = 0.61$). The mean LH, FSH and SHBG concentrations were within the respective reference ranges. Based on FT calculations, 17 (85%) patients were biochemically hypogonadal with 15 (75%) at less than 180 pmol/L and two (10%) patients between 180 and 250 pmol/L.

Assessment of Bone Mineral Density

The 17 male patients diagnosed as hypogonadal through calculated free testosterone (FT) were considered for assessment of bone mineral density. Three patients were excluded (one patient was excluded on the basis that the primary indication for IDD use was spinal osteoporosis, one patient had the intrathecal opioid therapy discontinued and one patient passed away).

The median age of the 14 patients at the time of BMD assessment was 62.5 years (48-70). The BMI score was 29.4 kg/m² (20.1-45.4). According to the BMI score, the majority of the patients (64.3%) were either overweight or obese and none of the patients were underweight.

Table 2 shows the results of the BMD assessment. Individual T-scores below -1.0 SD in at least one site were identified in 10 (71.4%) of the participants. Osteopenia defined as a T-score between -1.0 and -2.5 SD was observed in seven (50%) of the patients. Osteoporosis defined as a T-score at or below -2.5 SD was detected in three (21.4%) of the subjects. When considering the Z-scores, one (7.1%) of the participants presented a value at or below -2.5 SD indicating osteoporosis and four (28.6%) other patients Z-scores between -1.0 and -2.5 SD representative of osteopenia.

Table 2. Bone Mineral Density measurements

Site of measurement	BMD (g/cm ²)	T-score	Z-score
Femoral neck (n = 14)	0.925 (0.734 - 1.176)	-1.10 (-2.6 - 0.8)	-0.10 (-1.9 - 2.0)
Total hip (n = 14)	0.947 (0.686 - 1.222)	-1.10 (-3.1 - 1.0)	-0.40 (-2.6 - 1.9)
Forearm (n = 10)	0.736 (0.665 - 0.845)	-0.40 (-3.2 - 1.2)	0.30 (-2.4 - 1.7)
Lumbar (n = 4)	1.185 (0.876 - 1.487)	-0.40 (-2.4 - 2.0)	0.00 (-1.9 - 2.3)

Key: BMD - Bone Mineral Density

Statistics are presented as median (minimum-maximum)

Seven of the subjects had T-scores below -1.0 SD in more than one assessed site (Table 3). Three patients had either osteoporosis and/or osteopenia in two sites and four patients in three sites. Three of the participants presented Z-scores lower than -1.0 SD in three sites and one patient in two sites. No statistical differences were observed between the patients within normal reference range values and those with osteopenia or osteoporosis for age ($p = 0.72$) or BMI ($p = 0.48$).

Table 3. Bone Mineral Density outcomes

Site of measurement	Normal	Osteopenia ^a	Osteoporosis ^b
Femoral neck (n = 14)	7 / 14 (50%)	5 / 14 (35.7%)	2 / 14 (14.3%)
Total hip (n = 14)	7 / 14 (50%)	4 / 14 (28.6%)	3 / 14 (21.4%)
Forearm (n = 10)	7 / 10 (70%)	2 / 10 (20%)	1 / 10 (10%)
Lumbar (n = 4)	2 / 4 (50%)	2 / 4 (50%)	

^a Osteopenia was defined as $-2.5 \text{ SD} < \text{T-score} < -1.0 \text{ SD}$

^b Osteoporosis was defined as $\text{T-score} \leq -2.5 \text{ SD}$

Values represent the number of patients/total patients (%)

Several known clinical risk factors for low bone mineral density were present in this sample including hypogonadism in all of the patients. Although no incident fractures occurred in the studied group, assessment of the ten year probability of major osteoporotic or hip fracture based on the FRAX tool indicated a median probability of 5.7% (2.3-17) for major osteoporotic fracture and 1.1% (0.1-11) for hip fracture. Five (35.7%) of the participants were at or above the intervention threshold for hip fracture.

DISCUSSION

Our study showed that 85% of male patients on intrathecal opioid therapy were biochemically hypogonadal. The serum gonadotropin (LH and FSH) levels in these patients were inappropriately low or low-normal despite low serum testosterone concentrations, suggesting that testosterone suppression was caused through an inhibition of pituitary FSH and LH secretion (secondary hypogonadism). In a group of cancer survivors on opioids, 90% exhibited hypogonadism and low testosterone levels; LH levels but not FSH levels were found to be significantly lower when compared with cancer survivors not on opioid therapy.[20] The important role of endogenous opioids in the control of LH secretion has been demonstrated [21] and suppression of the hypothalamic-pituitary-gonadal axis by intrathecal opioids may be caused by a similar mechanism to that of endogenous opioids.[22] Nevertheless, the suppression of LH levels may be less accentuated when the opioids are administered orally or transdermally rather than intrathecally.[12]

1
2
3
4
5 Several possible factors may affect the sexual function in this group of patients.
6

7 Psychological aspects such as depression, passive coping strategies and catastrophising
8 are some of the factors hypothesized to influence the sexual function in chronic pain
9 patients.[23] However, chronic pain did not seem to be the cause of gonadal function
10 reduction in patients undertaking intrathecal morphine therapy when compared with a control
11 group of chronic pain patients who were not taking any form of opioid drugs.[22] Of the
12 possible chronic illnesses identified in a longitudinal study with 890 male participants, only
13 cancer (9%) was associated with a greater decrease in testosterone levels than the
14 decrease that occurred with ageing alone.[24]
15
16
17
18
19
20
21
22
23
24

25 Hypogonadism is an important risk factor for the development of osteoporosis in both
26 sexes.[16] To our knowledge, the incidence of osteopaenia or osteoporosis in patients
27 undertaking intrathecal opioid therapy has not been previously reported. In our study, 50% of
28 patients had osteopenia and 21.4% had osteoporosis. Interestingly, an association between
29 oral opioid administration and reduced BMD was demonstrated in one study but the
30 presence or absence of hypogonadism was not assessed.[25] In a cross-sectional study,
31 osteopenia was present in 50% of the male patients undertaking oral opioids [26] but again it
32 was not clear if those patients were hypogonadal.
33
34
35
36
37
38
39
40
41
42

43 An association between oral opioid medication and an increase in fracture risk has also been
44 reported [27] but assessment of bone mineral density was not performed. The authors
45 suggested that this increase in fracture risk was possibly related to the risk of falls due to the
46 central nervous system side effect of dizziness caused by oral opioids. Opioid-induced
47 dizziness is less likely to occur in IDD patients since only a fraction of the opioid delivered
48 via intrathecal route reaches the brain. Low bone mass is an important component of the risk
49 of fracture as well as non-skeletal factors such as propensity to fall.[16,28] Many fragility
50
51
52
53
54
55
56
57
58
59
60

1
2
3 fractures occur in the absence of osteoporosis, although in the presence of this disease, the
4 risk of fracture is higher.[29] Osteoporotic fractures are a significant cause of morbidity and
5 mortality especially in the developed countries,[30] and are associated with increased
6 mortality, particularly in men.[31]
7
8
9

10
11
12 The assumption that hypogonadism is a risk factor for decreased BMD has not always been
13 confirmed in the literature. No association between age-related hypogonadism (based on
14 total testosterone) and decreased BMD was found in elderly men.[32] In contrast, free
15 testosterone (calculated according to the Vermeulen equation) was demonstrated to be an
16 independent predictor of BMD and fractures in elderly men [33] and a positive predictor of
17 cortical bone size in young men at the age of peak bone mass.[34] These contradictory
18 findings may have occurred because free testosterone is more important physiologically than
19 total testosterone. SHBG levels, which generally are genetically determined, seem to play an
20 important role in bone mass, hence the reason for free testosterone to be a stronger
21 predictor than total testosterone alone. Recently it has been suggested that SHBG levels in
22 healthy adult men at the age of peak bone mass were positively associated with cortical
23 bone size independently of sex-steroid levels.[35] However, in middle aged and elderly men,
24 SHBG elevation was significantly associated with the occurrence of osteoporotic
25 fractures.[36] Although not yet confirmed, it has been suggested that the effect of SHBG on
26 BMD may change with age and/or testosterone sufficiency or deficiency.[37]
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46 It is important to note the limitations of this study. A small number of patients were included
47 without a control group. The gonadal status and bone mineral density were not evaluated
48 prior to commencement of IDD therapy. Women were not included in this study. Low libido
49 and amenorrhea have been reported in female IDDS patients,[17,22] although the
50 prevalence has been reported to be lower in women.[26] A large meta-analysis, which
51 included approximately 39,000 men and women has concluded that the age-specific risk of
52
53
54
55
56
57
58
59
60

1
2
3 hip fracture is similar in both men and women with the same BMD and age.[38] Despite
4 these limitations, the results of BMD assessment suggest that the IDD population may have
5 an increased risk for osteoporotic fractures.
6
7
8
9

10
11 It is important to provide appropriate treatment to patients with low BMD. FRAX analysis is a
12 simple tool that can be used to identify of patients in whom osteoporosis prophylaxis is
13 appropriate by taking into account multiple risk factors including BMD levels and
14 hypogonadism. BMD can be normalized and maintained within the normal range in men with
15 either primary or secondary hypogonadism by continuous, long-term hormonal replacement
16 therapy [39] though the full effect on BMD may take up to 24 months.[40]
17
18
19
20
21
22
23
24

25 This study suggests an important association between hypogonadism and low bone mass
26 density in patients undertaking intrathecal opioid delivery for the management of chronic
27 non-malignant pain. Early detection of hypogonadism followed by appropriate treatment may
28 be paramount to reduce the risk of osteoporosis development and prevention of fractures in
29 this population. Furthermore, surveillance of BMD levels in hypogonadal intrathecal opioid
30 delivery patients should be considered.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article focus

- Hypogonadism is common in intrathecal opioid therapy patients but there is limited literature investigating bone mineral density in this population.
- We aimed to prospectively investigate if undiagnosed hypogonadism in intrathecal opioid therapy patients may result in low bone mineral density levels.

Key messages

- Undiagnosed hypogonadism in intrathecal opioid therapy patients may lead to low bone mineral density levels.
- Hypogonadism and bone mineral density levels surveillance may be paramount to reduce the risk of osteoporosis and fractures in patients undertaking intrathecal opioid therapy.

Strengths and limitations of this study

- To our knowledge, this is the first study to specifically address the potential decrease in bone mineral density as a consequence of long-term intrathecal opioid therapy.
- Further studies are warranted to assess the effectiveness of early detection and adequate treatment to prevent bone mineral density decrease and to investigate the value of hormonal replacement therapy to normalise bone mineral density levels.

Acknowledgments

The authors are grateful to Dr Jane Dale from the Department of Endocrinology and Diabetes at Russells Hall Hospital for her comments on the final version of this manuscript.

Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests statement

The authors report no conflicts of interest.

Contributorship statement

RVD, JHR, JLS, MHL, AJW and RLA have made substantial contributions to (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be submitted.

Ethics approval

All assessments were performed as part of routine clinical care. No additional procedures were carried out for research purposes.

REFERENCES

- 1 Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. *Mayo Clin Proc* 1981;56:516-20.
- 2 Grady K, Raphael J. Spinal administration. In: Rice A. ed. *Textbook of Clinical Pain Management: Chronic Volume*. London: Hodder Arnold 2008:284-91.
- 3 Nordberg G, Hedner T, Mellstrand T, et al. Pharmacokinetic aspects of intrathecal morphine analgesia. *Anesthesiology* 1984;60:448-54.
- 4 Bernards C. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. *Anesthesiology* 2006;105:169-178.
- 5 Duarte RV, Raphael JH, Sparkes E, et al. Long-term intrathecal drug administration for chronic nonmalignant pain. *J Neurosurg Anesthesiol* 2012;24:63-70.
- 6 Duarte RV, Raphael JH, Haque MS, et al. A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain. *Pain Physician* 2012;15:363-69.

- 1
2
3 7 Doleys D, Dinoff B, Page L, et al. Sexual dysfunction and other side effects of intraspinal
4 opiate use in the management of chronic non-cancer pain. *American Journal of Pain*
5 *Management* 1998;8:5-11.
6
7
8
9 8 Reddy RG, Aung T, Karavitaki N, et al. Opioid induced hypogonadism. *BMJ*
10 2010;341:c4462.
11
12
13 9 Duarte RV, Raphael JH, Mourad Labib, et al. Prevalence and influence of diagnostic
14 criteria in the assessment of hypogonadism in intrathecal opioid therapy patients. *Pain*
15 *Physician* 2013;16:9-14.
16
17
18
19 10 Katz N, Mazer NA. The impact of opioids on the endocrine system. *Clin J Pain*
20 2009;25:170-5.
21
22
23 11 Petak SM, Nankin HR, Spark RF, et al. American Association of Clinical Endocrinologists
24 Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism
25 in adult male patients - 2002 update. *Endocr Pract* 2002;8:440-56.
26
27
28
29 12 Vuong C, Van Uum SHM, O'Dell LE, et al. The effects of opioids and opioid analogs on
30 animal and human endocrine systems. *Endocr Rev* 2010;31:98-132.
31
32
33 13 Schulz R, Wilhelm A, Pirke KM, et al. Beta-endorphin and dynorphin control serum
34 luteinizing hormone level in immature female rats. *Nature* 1981;294:757-9.
35
36
37 14 Pfeiffer DG, Pfeiffer A, Shimohigashi Y, et al. Predominant involvement of mu-rather than
38 delta- or kappa-opiate receptors in LH secretion. *Peptides* 1983;4:647-9.
39
40
41 15 Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the
42 estimation of free testosterone in serum. *J Clin Endocrinol Metab* 1999;84:3666-72.
43
44
45 16 Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. *Lancet*
46 2002;359:1929-36.
47
48
49 17 Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal
50 administration of opioids. *J Clin Endocrinol Metab* 2000;85:2215-22.
51
52
53 18 Hackett G, Cole NS, Deshpande AA, et al. Biochemical hypogonadism in men with type 2
54 diabetes in primary care practice. *Br J Diabetes Vasc Dis* 2009;9:226-31.
55
56
57
58
59
60

- 1
2
3 19 Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in
4 men and women from the UK. *Osteoporos Int* 2008;19:385-97.
5
6
7 20 Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al. Symptomatic hypogonadism in
8 male survivors of cancer with chronic exposure to opioids. *Cancer* 2004;100:851-8.
9
10
11 21 Genazzani AR, Genazzani AD, Volpogni C, et al. Opioid control of gonadotrophin
12 secretion in humans. *Hum Reprod* 1993;8(Suppl 2):151-3.
13
14
15 22 Finch P, Roberts L, Price L, et al. Hypogonadism in patients treated with intrathecal
16 morphine. *Clin J Pain* 2000;16:251-4.
17
18
19 23 Monga TN, Tan G, Ostermann HJ, et al. Sexuality and sexual adjustment of patients with
20 chronic pain. *Disabil Rehabil* 1998;20:317-29.
21
22
23 24 Harman S, Metter E, Tobin J, et al. Longitudinal effects of aging on serum total and free
24 testosterone levels in healthy men. *J Clin Endocrinol Metab* 2001;86:724-31.
25
26
27 25 Kinjo M, Setoguchi S, Schneeweiss S, et al. Bone mineral density in subjects using
28 central nervous system-active medications. *Am J Med* 2005;118:1414.
29
30
31 26 Fraser LA, Morrison D, Morley-Forster P, et al. Oral opioids for chronic non-cancer pain:
32 higher prevalence of hypogonadism in men than in women. *Exp Clin Endocrinol Diabetes*
33 2009;117:38-43.
34
35
36
37 27 Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of
38 morphine and opiates. *J Inter Med* 2006;260:76-87.
39
40
41 28 Center JR, Nguyen TV, Sambrook PN, et al. Hormonal and biochemical parameters and
42 osteoporotic fractures in elderly men. *J Bone Miner Res* 2000;15:05-1411.
43
44
45 29 Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. *J Bone Miner*
46 *Res* 1994;9:1137-41.
47
48
49 30 Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated
50 with osteoporotic fractures. *Osteoporos Int* 2006;17:1726-33.
51
52
53 31 Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic
54 fracture in men and women: an observational study. *Lancet* 1999;353:878-82.
55
56
57
58
59
60

- 1
2
3 32 Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with
4 bone mineral density in elderly men from the Framingham study. *Ann Intern Med*
5 2000;133:951-63.
6
7
8
9 33 Mellström D, Johnell O, Ljunggren O, et al. Free testosterone is an independent predictor
10 of BMD and prevalent fractures in elderly men: MrOS Sweden. *J Bone Miner Res*
11 2006;21:529-35.
12
13
14 34 Lorentzon M, Swanson C, Andersson N, et al. Free testosterone is a positive, whereas
15 free estradiol is a negative, predictor of cortical bone size in young Swedish men: the
16 GOOD study. *J Bone Miner Res* 2005;20:1334-41.
17
18
19
20
21 35 Vanbillemont G, Lapauw B, Bogaert V, et al. Sex hormone-binding globulin as an
22 independent determinant of cortical bone status in men at the age of peak bone mass. *J*
23 *Clin Endocrinol Metab* 2010;95:1579-86.
24
25
26
27 36 Hoppé E, Bouvard B, Royer M, et al. Sex hormone-binding globulin in osteoporosis. *Joint*
28 *Bone Spine* 2010;77:306-312.
29
30
31 37 Khosla S. Sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid
32 action? *J Clin Endocrinol Metab* 2006;91:4764-6.
33
34
35
36 38 Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. *J*
37 *Bone Miner Res* 2005;20:1185-94.
38
39
40 39 Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean
41 body mass during testosterone administration in men with acquired hypogonadism. *J Clin*
42 *Endocrinol Metab* 1996;81:4358-65.
43
44
45
46 40 Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in
47 hypogonadal men. *J Clin Endocrinol Metab* 2000;85:2670-77.
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract Page 2 (b) Provide in the abstract an informative and balanced summary of what was done and what was found Page 2
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 2-4
Objectives	3	State specific objectives, including any prespecified hypotheses Page 4
Methods		
Study design	4	Present key elements of study design early in the paper Page 4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 4,5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Page 4-6 <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 4,5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 4,5
Bias	9	Describe any efforts to address potential sources of bias Page 4
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page 6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding Page 6 (b) Describe any methods used to examine subgroups and interactions Page 6 (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Continued on next page

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page 6,7 (b) Give reasons for non-participation at each stage Page 7 (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Page 6-8 (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time Page 7-9 <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Page 7 (b) Report category boundaries when continuous variables were categorized Page 5-6 (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18	Summarise key results with reference to study objectives Page 9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Page 11,12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Page 9-12
Generalisability	21	Discuss the generalisability (external validity) of the study results Page 12

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Page 13
---------	----	--

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002856.R1
Article Type:	Research
Date Submitted by the Author:	13-Apr-2013
Complete List of Authors:	Duarte, Rui; Birmingham City University, Faculty of Health; Russells Hall Hospital, Department of Pain Management Raphael, Jon; Birmingham City University, Faculty of Health; Russells Hall Hospital, Department of Pain Management Southall, Jane; Russells Hall Hospital, Department of Pain Management Labib, Mourad; Russells Hall Hospital, Department of Clinical Biochemistry Whallett, Andrew; Russells Hall Hospital, Department of Rheumatology Ashford, Robert; Birmingham City University, Faculty of Health
Primary Subject Heading:	Anaesthesia
Secondary Subject Heading:	Neurology
Keywords:	chronic pain, hypogonadism, drug delivery systems, implantable, bone density

SCHOLARONE™
Manuscripts

1
2
3 **Hypogonadism and low bone mineral density in patients on long-term intrathecal**
4 **opioid delivery therapy**

5
6 Rui V. Duarte,^{1,2} Jon H. Raphael,^{1,2} Jane L. Southall,² Mourad H. Labib,³ Andrew J.
7 Whallett,⁴ Robert L. Ashford¹

8
9 ¹ Faculty of Health, Birmingham City University, Birmingham, UK

10 ² Department of Pain Management, Russells Hall Hospital, Dudley, UK

11 ³ Department of Clinical Biochemistry, Russells Hall Hospital, Dudley, UK

12 ⁴ Department of Rheumatology, Russells Hall Hospital, Dudley, UK
13
14
15
16
17

18 Name and address for correspondence: Rui V. Duarte, Faculty of Health, Birmingham City
19 University, City South Campus, Room 220 Ravensbury House, B15 3TN, Birmingham,
20 United Kingdom
21
22

23
24 Tel.: +44 24768 88063; Fax: +44 0121 331 6076; Email: ruivduarte@gmail.com
25
26
27

28 Keywords: bone density; chronic pain; hypogonadism; drug delivery systems, implantable
29

30 Word count: 2,675
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives

This study aimed to investigate the hypothalamic-pituitary-gonadal axis in a sample of male patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain and the presence of osteopenia and/or osteoporosis in those diagnosed with hypogonadism.

Design

Observational study using health data routinely collected for non-research purposes.

Setting

Department of Pain Management, Russells Hall Hospital, Dudley, United Kingdom.

Patients

Twenty consecutive male patients attending follow-up clinics for intrathecal opioid therapy had the gonadal axis evaluated by measuring their serum luteinising hormone, follicle stimulating hormone, total testosterone, sex hormone binding globulin and calculation of free testosterone. Bone mineral density was measured by DEXA scanning in those patients diagnosed with hypogonadism.

Results

Based on calculated free testosterone concentrations, 17 (85%) patients had biochemical hypogonadism with 15 patients (75%) having free testosterone <180 pmol/L and 2 patients (10%) between 180 and 250 pmol/L. Bone mineral density was assessed in 14 of the 17 patients after the exclusion of 3 patients. Osteoporosis (defined as a T-score \leq -2.5 SD) was detected in three patients (21.4%) and osteopenia (defined as a T-score between -1.0 and -2.5 SD) was observed in seven patients (50%). Five of the 14 patients (35.7%) were at or above the intervention threshold for hip fracture.

Conclusion

This study suggests an association between hypogonadism and low bone mass density in patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain. Surveillance of hypogonadism and bone mineral density levels followed by appropriate treatment may be paramount to reduce the risk of osteoporosis development and prevention of fractures in this group of patients.

INTRODUCTION

Treatment strategies for the management of chronic pain start with the lowest risk and least invasive intervention and progress if a treatment is not effective. Intrathecal drug delivery

1
2
3 (IDD) is considered a last resort treatment for the management of severe chronic pain due to
4 its invasive nature, concerns about long-term opioid use, and the possible complications
5 related to this modality of treatment. Intrathecal spinal analgesia has become a recognized
6 treatment for chronic non-malignant pain since the first reservoir was implanted in 1981.[1]
7
8 The use of opioids via intrathecal drug delivery allows for a selective concentration to reach
9 an important site of pain transmission, the spinal cord dorsal horn.[2] Opioid administration
10 into the intrathecal space achieves its effects at lower doses than using the epidural route.[3]
11
12 The drug is highly localized, so its analgesic efficacy is maximized at lower doses.[4]
13
14 Moreover, opioid dose escalation throughout the years may be modest.[5,6] These factors
15 lead to a decrease in the possible opioid side-effects.
16
17
18
19
20
21
22
23
24

25 The potential effect of intrathecal opioid delivery on the endocrine system is one of the least
26 recognised and investigated.[7] Currently, opioid-induced hypogonadism is under-
27 recognised and undertreated.[8,9] Some patients may attribute the signs and symptoms of
28 hypogonadism; such as decreased libido, tiredness, loss of muscle mass and strength,
29 among others, to the chronic pain and its related conditions rather than to the intrathecal
30 medication.[7, 10] Moreover, symptoms of hypogonadism are often neither disclosed by the
31 patient nor documented by the physician.[11] The current limited clinical awareness of the
32 opioid effects on the endocrine system, together with the lack of information on their long-
33 term consequences, is likely to result in a lack of information provision to the patient when
34 long-term opioid therapy is being considered.[12]
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Animal studies suggest that opioids affect gonadotropin release via the inhibition of the
49 gonadotropin releasing hormone (GnRH) by β -endorphin,[13] most likely at μ -receptors.[14]
50 This inhibition reduces the release of luteinizing hormone (LH) and follicle stimulating
51 hormone (FSH) by the pituitary gland and consequently the production of testosterone by the
52 gonads, resulting in hypogonadism and loss of libido. This is characterized by low or low-
53
54
55
56
57
58
59
60

1
2
3 normal LH and FSH levels, and low testosterone levels.[11] Most circulating testosterone is
4 bound to sex hormone-binding globulin (SHBG). A lesser fraction is non-specifically bound to
5 albumin and only a small percentage of testosterone is unbound.[15] Historically, free
6 testosterone was thought to be the only biologically-active component. However,
7 testosterone is weakly bound to serum albumin and dissociates freely in the capillary bed,
8 and is readily available for tissue uptake. All non-SHBG-bound testosterone is therefore
9 considered bioavailable.
10

11 Hypogonadism is an important risk factor for development of osteoporosis in both sexes, but
12 opioids have not been considered as a risk factor.[16] To our knowledge, the assessment of
13 BMD in patients undertaking intrathecal drug delivery is limited to one study which
14 suggested a tendency towards decreased BMD in these patients but the prevalence of
15 osteopenia or osteoporosis in these patients was not reported in this study.[17]
16
17

18 The aim of this study was to investigate the hypothalamic-pituitary-gonadal axis in a sample
19 of male patients undertaking intrathecal opioid delivery for the management of chronic non-
20 malignant pain and to assess the prevalence of osteopenia and/or osteoporosis in those
21 diagnosed with hypogonadism.
22
23

24 **METHODS**

25 **Patients**

26 Twenty consecutive male patients attending follow-up clinics for IDD therapy at Russells Hall
27 Hospital, Dudley, UK, for the management of chronic non-cancer pain were included in this
28 observational study using health data routinely collected for non-research purposes. All
29 assessments were performed as part of routine clinical care. No additional procedures were
30 carried out for research purposes. None of these patients received testosterone
31 supplementation within the previous three months. The pain syndrome experienced by the
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 patients was classified as nociceptive (58.8%), neuropathic (5.8%) and mixed nociceptive-
4 neuropathic (35.3%). All the patients were receiving intrathecal opioids for the management
5 of their pain. Intrathecal morphine was the only medication administered to 50% of the
6 sample. In individual cases, other substances were added to the intrathecal medication, with
7 combinations of morphine with bupivacaine (12.5%), morphine with bupivacaine and
8 clonidine (25%), and morphine with bupivacaine and baclofen (12.5%).
9
10
11
12
13
14
15
16

17 **Laboratory Methods**

18
19 Blood samples were collected between 8am and 11am during a seven-month period (April to
20 October 2010), as part of routine clinical care, for the measurement of serum LH, FSH,
21 prolactin (PRL), total testosterone (TT) and SHBG. All assays were carried out by the
22 Department of Clinical Biochemistry at Russells Hall Hospital, Dudley, UK. LH, FSH, PRL
23 and TT were measured according to the manufacturer's instructions by immuno-
24 enzymometric fluorimetric assay on the Tosoh AIA 2000 LA analyser (Tosoh Bioscience
25 N.V., Tessenderlo, Belgium). The inter-assay imprecision (%CV) quoted by the manufacturer
26 was 2.6% for LH, 2.3% for FSH and 5.3% for testosterone. SHBG was measured according
27 to the manufacturer's instructions by chemiluminescent immunometric assay on the Immulite
28 2000 XPi analyser (Siemens Healthcare Diagnostics Ltd, Camberley, Surrey, UK). The inter-
29 assay variability (%CV) for SHBG was 5%. Calculations of free testosterone (FT) were
30 carried out using the Vermeulen equation.[15] The quoted reference ranges were: LH (2.2-
31 13.3 IU/L), FSH (1-7 IU/L), SHBG (13-71 nmol/L) and PRL (0-445 mU/L). Serum TT < 8
32 nmol/L and/or FT < 180 pmol/L was considered as biochemical hypogonadism. Serum TT 8
33 – 12 nmol/L and/or FT 180-250 pmol/L was considered as borderline/low.[18]
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Assessment of Bone Mineral Density**

52
53 Bone mineral density was measured by DEXA scanning of the femur (neck and hip) and
54 lumbar spine or left forearm using the Lunar Prodigy DEXA (GE Lunar Corp., Madison, WI,
55
56
57
58
59
60

1
2
3 USA). Bone densitometry DEXA scans were carried out by the Department of Radiology, at
4 Corbett Hospital, Dudley, UK. Lumbar spine scan was not carried out in patients who had
5 previous spinal surgery. In those cases, assessment was performed at the left forearm site.
6
7 Results are presented as BMD (g/cm^2), T-scores and Z-scores. Reference values for T-
8 score were based on UK (ages 20-40) femur, spine or forearm reference population (v107).
9
10 Osteopenia was defined as a T-score between -1.0 and -2.5 SD, and osteoporosis as a T-
11 score at or below -2.5 SD. Measurements of height, weight and body mass index (BMI) were
12 also performed. The BMI scores were categorised according to the World Health
13 Organisation key cut-off points as <18.5 (underweight), ≥ 18.5 and ≤ 24.9 (normal weight), \geq
14 25 and ≤ 29.9 (overweight), and $\geq 30 \text{ kg}/\text{m}^2$ (obese). The 10-year probability of fracture was
15 calculated based on the Fracture Risk Assessment Tool (FRAX).[19] In addition to the BMD
16 value or T-score (femoral neck), this tool takes into account clinical risk factors for the
17 development of osteoporotic or hip fractures such as previous fractures, history of hip
18 fracture in the patient's parents and hypogonadism, among other factors.
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **Data analysis**

34
35 Kolmogorov-Smirnov test was performed to test distribution of numerical data, followed by
36 the appropriate statistical tests. Comparisons between groups were carried out with the
37 Mann-Whitney test. Data is reported as median (minimum-maximum). The 95% confidence
38 intervals for the TT and FT median values were calculated for comparison with normal
39 reference values. Statistical significance was judged at 5% level. Statistical tests were
40 performed using Predictive Analytics SoftWare (PASW) (version 18.0, SPSS Inc., Chicago,
41 IL, USA).
42
43
44
45
46
47
48
49
50

51 **RESULTS**

52 **Assessment of Sex Hormones**

53
54
55 The median age at the time of blood collection was 58 years (47-69). The median duration
56
57
58
59
60

from implantation of the IDD system to hormone assay was 100 months (15-203) with an intrathecal opioid dose of 2.68 mg/day (range 1-9.7) (Table 1). The duration of pain prior to commencement of IDD was 9 years (range 3-35).

Table 1. Sample characteristics

Patients (N)	20
Age (years)	58 (47-69)
IDDS duration (months)	100 (15-203)
Opioid dose (mg/day)	2.68 (1-9.7)
LH (IU/L)	1.9 (0.2-19.9)
FSH (IU/L)	5.3 (0.3-23.9)
SHBG (nmol/L)	51 (17-123)
PRL (mU/L)	225 (53-614)
TT (nmol/L)	4.95 (1.2-18.8)
FT (pmol/L)	69.45 (14-328)

Key: LH - luteinizing hormone; FSH - follicle stimulating hormone; SHBG - sex hormone binding globulin; PRL - prolactin; TT – total testosterone; FT - free testosterone

Statistics are presented as median (minimum-maximum)

The median TT levels with 95% confidence intervals was 4.95 nmol/L (3.0-10.1), which were significantly lower than the cut-off level of 12 nmol/L for borderline/low testosterone. The median FT levels with 95% confidence intervals [69.45 (47.3-127.0)] were also significantly lower than the cut-off level of 180 pmol/L for low FT ($t = -3.403$, $p < 0.005$, $r = 0.61$). The mean LH, FSH and SHBG concentrations were within the respective reference ranges. Prolactin levels were above the reference range in two patients. One of these patients had low TT and FT and the other patient presented borderline/low TT. Based on TT, 17 (85%) of the patients presented biochemical hypogonadism values with 12 (60%) at less than 8 nmol/L and 5 (25%) with TT values between 8 and 12 nmol/L (borderline/low). Based on FT calculations, 17 (85%) patients were biochemically hypogonadal with 15 (75%) at less than 180 pmol/L and two (10%) patients between 180 and 250 pmol/L. Only one of the patients had TT and FT values within quoted reference ranges, two patients presented borderline/low

1
2
3 TT and normal FT, one patient had low FT values and normal TT, and one borderline/low FT
4 and normal TT.
5
6
7

8 9 **Assessment of Bone Mineral Density**

10
11 Considering that free testosterone reflects more accurately the clinical situation than total
12 testosterone in plasma, [15] the 17 male patients diagnosed as hypogonadal through
13 calculated FT were considered for assessment of bone mineral density. Three patients were
14 excluded (one patient was excluded on the basis that the primary indication for IDD use was
15 spinal osteoporosis, one patient had the intrathecal opioid therapy discontinued and one
16 patient passed away.
17
18
19
20
21
22
23
24

25 The median age of the 14 patients at the time of BMD assessment was 62.5 years (48-70).
26 All the patients investigated for BMD were Caucasian. The BMI score was 29.4 kg/m² (20.1-
27 45.4). According to the BMI score, the majority of the patients (64.3%) were either
28 overweight or obese and none of the patients were underweight.
29
30
31
32
33
34

35 Table 2 shows the results of the BMD assessment. Individual T-scores below -1.0 SD in at
36 least one site were identified in 10 (71.4%) of the patients. Osteopenia defined as a T-score
37 between -1.0 and -2.5 SD was observed in seven (50%) of the patients. Osteoporosis
38 defined as a T-score at or below -2.5 SD was detected in three (21.4%) of the subjects.
39
40
41
42
43 When considering the Z-scores, one (7.1%) of the participants presented a value at or below
44 -2.5 SD indicating osteoporosis and four (28.6%) other patients Z-scores between -1.0 and -
45 2.5 SD representative of osteopenia.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Bone Mineral Density measurements

Site of measurement	BMD (g/cm ²)	T-score	Z-score
Femoral neck (n = 14)	0.925 (0.734 - 1.176)	-1.10 (-2.6 - 0.8)	-0.10 (-1.9 - 2.0)
Total hip (n = 14)	0.947 (0.686 - 1.222)	-1.10 (-3.1 - 1.0)	-0.40 (-2.6 - 1.9)
Forearm (n = 10)	0.736 (0.665 - 0.845)	-0.40 (-3.2 - 1.2)	0.30 (-2.4 - 1.7)
Lumbar (n = 4)	1.185 (0.876 - 1.487)	-0.40 (-2.4 - 2.0)	0.00 (-1.9 - 2.3)

Key: BMD - Bone Mineral Density

Statistics are presented as median (minimum-maximum)

Seven of the subjects had T-scores below -1.0 SD in more than one assessed site (Table 3).

Three patients had either osteoporosis and/or osteopenia in two sites and four patients in three sites. Three of the patients presented Z-scores lower than -1.0 SD in three sites and one patient in two sites. No statistical differences were observed between the patients within normal reference range values and those with osteopenia or osteoporosis for age ($p = 0.72$) or BMI ($p = 0.48$).

Table 3. Bone Mineral Density outcomes

Site of measurement	Normal	Osteopenia ^a	Osteoporosis ^b
Femoral neck (n = 14)	7 / 14 (50%)	5 / 14 (35.7%)	2 / 14 (14.3%)
Total hip (n = 14)	7 / 14 (50%)	4 / 14 (28.6%)	3 / 14 (21.4%)
Forearm (n = 10)	7 / 10 (70%)	2 / 10 (20%)	1 / 10 (10%)
Lumbar (n = 4)	2 / 4 (50%)	2 / 4 (50%)	

^a Osteopenia was defined as $-2.5 \text{ SD} < \text{T-score} < -1.0 \text{ SD}$

^b Osteoporosis was defined as $\text{T-score} \leq -2.5 \text{ SD}$

Values represent the number of patients/total patients (%)

Several known clinical risk factors for low bone mineral density were present in this sample including hypogonadism in all of the patients. Investigation of osteoporosis related fractures through x-rays were not performed. Although the patients in the studied group did not report any incident fractures, assessment of the ten-year probability of major osteoporotic or hip fracture based on the FRAX tool indicated a median probability of 5.7% (2.3-17) for major osteoporotic fracture and 1.1% (0.1-11) for hip fracture. Five (35.7%) of the patients were at or above the intervention threshold for hip fracture.

DISCUSSION

Our study showed that 85% of male patients on intrathecal opioid therapy were biochemically hypogonadal. The serum gonadotropin (LH and FSH) levels in these patients were inappropriately low or low-normal despite low serum testosterone concentrations, suggesting that testosterone suppression was caused through an inhibition of pituitary FSH and LH secretion (secondary hypogonadism). Raised serum prolactin may have contributed to the low testosterone in two patients. Although acute administration of morphine leads to an increase in PRL levels,[12] tolerance usually develops during chronic administration.[20] Previous studies investigating chronic administration of intrathecal morphine have also reported a small proportion of patients with elevated PRL levels.[17,21] In a group of cancer survivors on opioids, 90% exhibited hypogonadism and low testosterone levels; LH levels but not FSH levels were found to be significantly lower when compared with cancer survivors not on opioid therapy.[22] The important role of endogenous opioids in the control of LH secretion has been demonstrated [23] and suppression of the hypothalamic-pituitary-gonadal axis by intrathecal opioids may be caused by a similar mechanism to that of endogenous opioids.[24] Nevertheless, the suppression of LH levels may be less accentuated when the opioids are administered orally or transdermally rather than intrathecally.[12]

Several possible factors may affect the sexual function in this group of patients. Psychological aspects such as depression, passive coping strategies and catastrophising are some of the factors hypothesized to influence the sexual function in chronic pain patients.[25] However, chronic pain did not seem to be the cause of gonadal function reduction in patients undertaking intrathecal morphine therapy when compared with a control group of chronic pain patients who were not taking any form of opioid drugs.[24] Of the possible chronic illnesses identified in a longitudinal study with 890 male participants, only

1
2
3 cancer (9%) was associated with a greater decrease in testosterone levels than the
4 decrease that occurred with ageing alone.[26]
5
6
7

8
9 Hypogonadism is an important risk factor for the development of osteoporosis in both
10 sexes.[16] To our knowledge, the incidence of osteopaenia or osteoporosis in patients
11 undertaking intrathecal opioid therapy has not been previously reported. In our study, 50% of
12 patients had osteopenia and 21.4% had osteoporosis. Interestingly, an association between
13 oral opioid administration and reduced BMD was demonstrated in one study but the
14 presence or absence of hypogonadism was not assessed.[27] In a cross-sectional study,
15 osteopenia was present in 50% of the male patients undertaking oral opioids [28] but again it
16 was not clear if those patients were hypogonadal.
17
18
19
20
21
22
23
24
25
26

27 An association between oral opioid medication and an increase in fracture risk has also been
28 reported [29] but assessment of bone mineral density was not performed. The authors
29 suggested that this increase in fracture risk was possibly related to the risk of falls due to the
30 central nervous system side effect of dizziness caused by oral opioids. Opioid-induced
31 dizziness is less likely to occur in IDD patients since only a fraction of the opioid delivered
32 via intrathecal route reaches the brain. Low bone mass is an important component of the risk
33 of fracture as well as non-skeletal factors such as propensity to fall.[16,30] Many fragility
34 fractures occur in the absence of osteoporosis, although in the presence of this disease, the
35 risk of fracture is higher.[31] Osteoporotic fractures are a significant cause of morbidity and
36 mortality especially in the developed countries,[32] and are associated with increased
37 mortality, particularly in men.[33]
38
39
40
41
42
43
44
45
46
47
48
49
50

51 The assumption that hypogonadism is a risk factor for decreased BMD has not always been
52 confirmed in the literature. No association between age-related hypogonadism (based on
53 total testosterone) and decreased BMD was found in elderly men.[34] In contrast, free
54
55
56
57
58
59
60

1
2
3 testosterone (calculated according to the Vermeulen equation) was demonstrated to be an
4 independent predictor of BMD and fractures in elderly men [35] and a positive predictor of
5 cortical bone size in young men at the age of peak bone mass.[36] These contradictory
6 findings may have occurred because free testosterone is more important physiologically than
7 total testosterone. SHBG levels, which generally are genetically determined, seem to play an
8 important role in bone mass, hence the reason for free testosterone to be a stronger
9 predictor than total testosterone alone. Recently it has been suggested that SHBG levels in
10 healthy adult men at the age of peak bone mass were positively associated with cortical
11 bone size independently of sex-steroid levels.[37] However, in middle aged and elderly men,
12 SHBG elevation was significantly associated with the occurrence of osteoporotic
13 fractures.[38] Although not yet confirmed, it has been suggested that the effect of SHBG on
14 BMD may change with age and/or testosterone sufficiency or deficiency.[39]

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29 It is important to note the limitations of this study. A small number of patients were included
30 without a control group. The gonadal status and bone mineral density were not evaluated
31 prior to commencement of IDD therapy. Information on systemic opioids was not collected. A
32 proportion of these patients are provided with oral opioid medication on an individual basis
33 for occasional flare-ups. The strongest systemic opioid provided is tramadol at a dose ≤ 400
34 mg/day. Women were not included in this study. Low libido and amenorrhea have been
35 reported in female IDDS patients,[17,24] although the prevalence has been reported to be
36 lower in women.[28] A large meta-analysis, which included approximately 39,000 men and
37 women has concluded that the age-specific risk of hip fracture is similar in both men and
38 women with the same BMD and age.[40] Despite these limitations, the results of BMD
39 assessment suggest that the IDD population may have an increased risk for osteoporotic
40 fractures.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 It is important to provide appropriate treatment to patients with low BMD. FRAX analysis is a
4 simple tool that can be used to identify of patients in whom osteoporosis prophylaxis is
5 appropriate by taking into account multiple risk factors including BMD levels and
6
7 hypogonadism. BMD can be normalized and maintained within the normal range in men with
8
9 either primary or secondary hypogonadism by continuous, long-term hormonal replacement
10
11 therapy [41] though the full effect on BMD may take up to 24 months.[42] Opioid induced
12
13 hypogonadism may be reversible. Clinically significant improvements in hypogonadal
14
15 symptoms were observed in men with opioid induced androgen deficiency following
16
17 treatment with transdermal testosterone patches. [43] In patients undertaking intrathecal
18
19 opioid delivery, recovery of serum testosterone levels following cessation of therapy or
20
21 significant improvements in libido following hormonal replacement therapy have also been
22
23 reported.[17,24]
24
25
26
27
28

29 Further studies in this patient group are warranted. Future studies should prospectively
30
31 evaluate the gonadal axis, reported sexual health of the participants and BMD. It would also
32
33 be important to compare these results with matched cohorts of chronic pain patients.
34
35 Potential comparisons include patients on systemic opioids only, on a different course of
36
37 intrathecal therapy (e.g. ziconotide) or patients using spinal cord stimulation for the
38
39 management of their chronic pain.
40
41
42

43 This study suggests an important association between hypogonadism and low bone mass
44
45 density in patients undertaking intrathecal opioid delivery for the management of chronic
46
47 non-malignant pain. However, since the gonadal status and BMD were not determined prior
48
49 to initiation of intrathecal opioid delivery, we cannot conclude that the decreased BMD was
50
51 caused by hypogonadism or opioid administration. Early detection of hypogonadism followed
52
53 by appropriate treatment may be paramount to reduce the risk of osteoporosis development
54
55
56
57
58
59
60

1
2
3 and prevention of fractures in this population. Furthermore, surveillance of BMD levels in
4
5 hypogonadal intrathecal opioid delivery patients should be considered.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ARTICLE SUMMARY

Article focus

- Hypogonadism is common in intrathecal opioid therapy patients but there is limited literature investigating bone mineral density in this population.
- We aimed to prospectively investigate if undiagnosed hypogonadism in intrathecal opioid therapy patients may result in low bone mineral density levels.

Key messages

- Undiagnosed hypogonadism in intrathecal opioid therapy patients may lead to low bone mineral density levels.
- Hypogonadism and bone mineral density levels surveillance may be paramount to reduce the risk of osteoporosis and fractures in patients undertaking intrathecal opioid therapy.

Strengths and limitations of this study

- To our knowledge, this is the first study to specifically address the potential decrease in bone mineral density as a consequence of long-term intrathecal opioid therapy.
- Further studies are warranted to assess the effectiveness of early detection and adequate treatment to prevent bone mineral density decrease and to investigate the value of hormonal replacement therapy to normalise bone mineral density levels.

Acknowledgments

The authors are grateful to Dr Jane Dale from the Department of Endocrinology and Diabetes at Russells Hall Hospital for her comments on the final version of this manuscript.

Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests statement

The authors report no conflicts of interest.

Contributorship statement

RVD, JHR, JLS, MHL, AJW and RLA have made substantial contributions to (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be submitted.

Ethics approval

All assessments were performed as part of routine clinical care. No additional procedures were carried out for research purposes.

REFERENCES

- 1 Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. *Mayo Clin Proc* 1981;56:516-20.
- 2 Grady K, Raphael J. Spinal administration. In: Rice A. ed. *Textbook of Clinical Pain Management: Chronic Volume*. London: Hodder Arnold 2008:284-91.
- 3 Nordberg G, Hedner T, Mellstrand T, et al. Pharmacokinetic aspects of intrathecal morphine analgesia. *Anesthesiology* 1984;60:448-54.
- 4 Bernards C. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. *Anesthesiology* 2006;105:169-178.
- 5 Duarte RV, Raphael JH, Sparkes E, et al. Long-term intrathecal drug administration for chronic nonmalignant pain. *J Neurosurg Anesthesiol* 2012;24:63-70.
- 6 Duarte RV, Raphael JH, Haque MS, et al. A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain. *Pain Physician* 2012;15:363-69.

- 1
2
3 7 Doleys D, Dinoff B, Page L, et al. Sexual dysfunction and other side effects of intraspinal
4 opiate use in the management of chronic non-cancer pain. *American Journal of Pain*
5 *Management* 1998;8:5-11.
6
7
8
9 8 Reddy RG, Aung T, Karavitaki N, et al. Opioid induced hypogonadism. *BMJ*
10 2010;341:c4462.
11
12
13 9 Duarte RV, Raphael JH, Mourad Labib, et al. Prevalence and influence of diagnostic
14 criteria in the assessment of hypogonadism in intrathecal opioid therapy patients. *Pain*
15 *Physician* 2013;16:9-14.
16
17
18
19 10 Katz N, Mazer NA. The impact of opioids on the endocrine system. *Clin J Pain*
20 2009;25:170-5.
21
22
23 11 Petak SM, Nankin HR, Spark RF, et al. American Association of Clinical Endocrinologists
24 Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism
25 in adult male patients - 2002 update. *Endocr Pract* 2002;8:440-56.
26
27
28
29 12 Vuong C, Van Uum SHM, O'Dell LE, et al. The effects of opioids and opioid analogs on
30 animal and human endocrine systems. *Endocr Rev* 2010;31:98-132.
31
32
33 13 Schulz R, Wilhelm A, Pirke KM, et al. Beta-endorphin and dynorphin control serum
34 luteinizing hormone level in immature female rats. *Nature* 1981;294:757-9.
35
36
37 14 Pfeiffer DG, Pfeiffer A, Shimohigashi Y, et al. Predominant involvement of mu-rather than
38 delta- or kappa-opiate receptors in LH secretion. *Peptides* 1983;4:647-9.
39
40
41 15 Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the
42 estimation of free testosterone in serum. *J Clin Endocrinol Metab* 1999;84:3666-72.
43
44
45 16 Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. *Lancet*
46 2002;359:1929-36.
47
48
49 17 Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal
50 administration of opioids. *J Clin Endocrinol Metab* 2000;85:2215-22.
51
52
53 18 Hackett G, Cole NS, Deshpande AA, et al. Biochemical hypogonadism in men with type 2
54 diabetes in primary care practice. *Br J Diabetes Vasc Dis* 2009;9:226-31.
55
56
57
58
59
60

- 1
2
3 19 Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in
4 men and women from the UK. *Osteoporos Int* 2008;19:385-97.
5
6
7 20 Morley JE. The endocrinology of the opiates and opioid peptides. *Metabolism*
8 1981;30:195-209.
9
10
11 21 Paice JA, Penn RD, Ryan WG. Altered sexual function and decreased testosterone in
12 patients receiving intraspinal opioids. *J Pain Symptom Manage* 1994;9:126-31.
13
14
15 22 Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al. Symptomatic hypogonadism in
16 male survivors of cancer with chronic exposure to opioids. *Cancer* 2004;100:851-8.
17
18
19 23 Genazzani AR, Genazzani AD, Volpogni C, et al. Opioid control of gonadotrophin
20 secretion in humans. *Hum Reprod* 1993;8(Suppl 2):151-3.
21
22
23 24 Finch P, Roberts L, Price L, et al. Hypogonadism in patients treated with intrathecal
24 morphine. *Clin J Pain* 2000;16:251-4.
25
26
27 25 Monga TN, Tan G, Ostermann HJ, et al. Sexuality and sexual adjustment of patients with
28 chronic pain. *Disabil Rehabil* 1998;20:317-29.
29
30
31 26 Harman S, Metter E, Tobin J, et al. Longitudinal effects of aging on serum total and free
32 testosterone levels in healthy men. *J Clin Endocrinol Metab* 2001;86:724-31.
33
34
35 27 Kinjo M, Setoguchi S, Schneeweiss S, et al. Bone mineral density in subjects using
36 central nervous system-active medications. *Am J Med* 2005;118:1414.
37
38
39 28 Fraser LA, Morrison D, Morley-Forster P, et al. Oral opioids for chronic non-cancer pain:
40 higher prevalence of hypogonadism in men than in women. *Exp Clin Endocrinol Diabetes*
41 2009;117:38-43.
42
43
44 29 Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of
45 morphine and opiates. *J Inter Med* 2006;260:76-87.
46
47
48 30 Center JR, Nguyen TV, Sambrook PN, et al. Hormonal and biochemical parameters and
49 osteoporotic fractures in elderly men. *J Bone Miner Res* 2000;15:05-1411.
50
51
52 31 Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. *J Bone Miner*
53 Res 1994;9:1137-41.
54
55
56
57
58
59
60

- 1
2
3 32 Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated
4 with osteoporotic fractures. *Osteoporos Int* 2006;17:1726-33.
5
6
7 33 Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic
8 fracture in men and women: an observational study. *Lancet* 1999;353:878-82.
9
10
11 34 Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with
12 bone mineral density in elderly men from the Framingham study. *Ann Intern Med*
13 2000;133:951-63.
14
15
16
17 35 Mellström D, Johnell O, Ljunggren O, et al. Free testosterone is an independent predictor
18 of BMD and prevalent fractures in elderly men: MrOS Sweden. *J Bone Miner Res*
19 2006;21:529-35.
20
21
22
23 36 Lorentzon M, Swanson C, Andersson N, et al. Free testosterone is a positive, whereas
24 free estradiol is a negative, predictor of cortical bone size in young Swedish men: the
25 GOOD study. *J Bone Miner Res* 2005;20:1334-41.
26
27
28
29 37 Vanbillemont G, Lapauw B, Bogaert V, et al. Sex hormone-binding globulin as an
30 independent determinant of cortical bone status in men at the age of peak bone mass. *J*
31 *Clin Endocrinol Metab* 2010;95:1579-86.
32
33
34
35 38 Hoppé E, Bouvard B, Royer M, et al. Sex hormone-binding globulin in osteoporosis. *Joint*
36 *Bone Spine* 2010;77:306-312.
37
38
39 39 Khosla S. Sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid
40 action? *J Clin Endocrinol Metab* 2006;91:4764-6.
41
42
43
44 40 Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. *J*
45 *Bone Miner Res* 2005;20:1185-94.
46
47
48 41 Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean
49 body mass during testosterone administration in men with acquired hypogonadism. *J Clin*
50 *Endocrinol Metab* 1996;81:4358-65.
51
52
53
54 42 Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in
55 hypogonadal men. *J Clin Endocrinol Metab* 2000;85:2670-77.
56
57
58
59
60

1
2
3 43 Daniell HW, Lentz R, Mazer NA. Open-label pilot study of testosterone patch therapy in
4
5 men with opioid-induced androgen deficiency. J Pain 2006;7:200-10.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **Hypogonadism and low bone mineral density in patients on long-term intrathecal**
4 **opioid delivery therapy**

5
6 Rui V. Duarte,^{1,2} Jon H. Raphael,^{1,2} Jane L. Southall,² Mourad H. Labib,³ Andrew J.
7 Whallett,⁴ Robert L. Ashford¹

8
9 ¹ Faculty of Health, Birmingham City University, Birmingham, UK

10 ² Department of Pain Management, Russells Hall Hospital, Dudley, UK

11 ³ Department of Clinical Biochemistry, Russells Hall Hospital, Dudley, UK

12 ⁴ Department of Rheumatology, Russells Hall Hospital, Dudley, UK
13
14
15
16
17

18 Name and address for correspondence: Rui V. Duarte, Faculty of Health, Birmingham City
19 University, City South Campus, Room 220 Ravensbury House, B15 3TN, Birmingham,
20 United Kingdom
21
22

23
24 Tel.: +44 24768 88063; Fax: +44 0121 331 6076; Email: ruivduarte@gmail.com
25
26
27

28 Keywords: bone density; chronic pain; hypogonadism; drug delivery systems, implantable
29

30 Word count: 2,675
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives

This study aimed to investigate the hypothalamic-pituitary-gonadal axis in a sample of male patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain and the presence of osteopenia and/or osteoporosis in those diagnosed with hypogonadism.

Design

Observational study using health data routinely collected for non-research purposes.

Setting

Department of Pain Management, Russells Hall Hospital, Dudley, United Kingdom.

Patients

Twenty consecutive male patients attending follow-up clinics for intrathecal opioid therapy had the gonadal axis evaluated by measuring their serum luteinising hormone, follicle stimulating hormone, total testosterone, sex hormone binding globulin and calculation of free testosterone. Bone mineral density was measured by DEXA scanning in those patients diagnosed with hypogonadism.

Results

Based on calculated free testosterone concentrations, 17 (85%) patients had biochemical hypogonadism with 15 patients (75%) having free testosterone <180 pmol/L and 2 patients (10%) between 180 and 250 pmol/L. Bone mineral density was assessed in 14 of the 17 patients after the exclusion of 3 patients. Osteoporosis (defined as a T-score \leq -2.5 SD) was detected in three patients (21.4%) and osteopenia (defined as a T-score between -1.0 and -2.5 SD) was observed in seven patients (50%). Five of the 14 patients (35.7%) were at or above the intervention threshold for hip fracture.

Conclusion

This study suggests an association between hypogonadism and low bone mass density in patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain. Surveillance of hypogonadism and bone mineral density levels followed by appropriate treatment may be paramount to reduce the risk of osteoporosis development and prevention of fractures in this group of patients.

INTRODUCTION

Treatment strategies for the management of chronic pain start with the lowest risk and least invasive intervention and progress if a treatment is not effective. Intrathecal drug delivery

1
2
3 (IDD) is considered a last resort treatment for the management of severe chronic pain due to
4 its invasive nature, concerns about long-term opioid use, and the possible complications
5 related to this modality of treatment. Intrathecal spinal analgesia has become a recognized
6 treatment for chronic non-malignant pain since the first reservoir was implanted in 1981.[1]
7
8 The use of opioids via intrathecal drug delivery allows for a selective concentration to reach
9 an important site of pain transmission, the spinal cord dorsal horn.[2] Opioid administration
10 into the intrathecal space achieves its effects at lower doses than using the epidural route.[3]
11
12 The drug is highly localized, so its analgesic efficacy is maximized at lower doses.[4]
13
14 Moreover, opioid dose escalation throughout the years may be modest.[5,6] These factors
15 lead to a decrease in the possible opioid side-effects.
16
17
18
19
20
21
22
23
24

25 The potential effect of intrathecal opioid delivery on the endocrine system is one of the least
26 recognised and investigated.[7] Currently, opioid-induced hypogonadism is under-
27 recognised and undertreated.[8,9] Some patients may attribute the signs and symptoms of
28 hypogonadism; such as decreased libido, tiredness, loss of muscle mass and strength,
29 among others, to the chronic pain and its related conditions rather than to the intrathecal
30 medication.[7, 10] Moreover, symptoms of hypogonadism are often neither disclosed by the
31 patient nor documented by the physician.[11] The current limited clinical awareness of the
32 opioid effects on the endocrine system, together with the lack of information on their long-
33 term consequences, is likely to result in a lack of information provision to the patient when
34 long-term opioid therapy is being considered.[12]
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Animal studies suggest that opioids affect gonadotropin release via the inhibition of the
49 gonadotropin releasing hormone (GnRH) by β -endorphin,[13] most likely at μ -receptors.[14]
50 This inhibition reduces the release of luteinizing hormone (LH) and follicle stimulating
51 hormone (FSH) by the pituitary gland and consequently the production of testosterone by the
52 gonads, resulting in hypogonadism and loss of libido. This is characterized by low or low-
53
54
55
56
57
58
59
60

1
2
3 normal LH and FSH levels, and low testosterone levels.[11] Most circulating testosterone is
4 bound to sex hormone-binding globulin (SHBG). A lesser fraction is non-specifically bound to
5 albumin and only a small percentage of testosterone is unbound.[15] Historically, free
6 testosterone was thought to be the only biologically-active component. However,
7 testosterone is weakly bound to serum albumin and dissociates freely in the capillary bed,
8 and is readily available for tissue uptake. All non-SHBG-bound testosterone is therefore
9 considered bioavailable.
10

11
12 Hypogonadism is an important risk factor for development of osteoporosis in both sexes, but
13 opioids have not been considered as a risk factor.[16] To our knowledge, the assessment of
14 BMD in patients undertaking intrathecal drug delivery is limited to one study which
15 suggested a tendency towards decreased BMD in these patients but the prevalence of
16 osteopenia or osteoporosis in these patients was not reported in this study.[17]
17
18

19
20 The aim of this study was to investigate the hypothalamic-pituitary-gonadal axis in a sample
21 of male patients undertaking intrathecal opioid delivery for the management of chronic non-
22 malignant pain and to assess the prevalence of osteopenia and/or osteoporosis in those
23 diagnosed with hypogonadism.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **METHODS**

42 **Patients**

43
44 Twenty consecutive male patients attending follow-up clinics for IDD therapy at Russells Hall
45 Hospital, Dudley, UK, for the management of chronic non-cancer pain were included in this
46 observational study using health data routinely collected for non-research purposes. All
47 assessments were performed as part of routine clinical care. No additional procedures were
48 carried out for research purposes. None of these patients received testosterone
49 supplementation within the previous three months. The pain syndrome experienced by the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 patients was classified as nociceptive (58.8%), neuropathic (5.8%) and mixed nociceptive-
4 neuropathic (35.3%). All the patients were receiving intrathecal opioids for the management
5 of their pain. Intrathecal morphine was the only medication administered to 50% of the
6 sample. In individual cases, other substances were added to the intrathecal medication, with
7 combinations of morphine with bupivacaine (12.5%), morphine with bupivacaine and
8 clonidine (25%), and morphine with bupivacaine and baclofen (12.5%).
9
10
11
12
13
14
15
16

17 **Laboratory Methods**

18
19 Blood samples were collected between 8am and 11am during a seven-month period (April to
20 October 2010), as part of routine clinical care, for the measurement of serum LH, FSH,
21 prolactin (PRL), total testosterone (TT) and SHBG. All assays were carried out by the
22 Department of Clinical Biochemistry at Russells Hall Hospital, Dudley, UK. LH, FSH, PRL
23 and TT were measured according to the manufacturer's instructions by immuno-
24 enzymometric fluorimetric assay on the Tosoh AIA 2000 LA analyser (Tosoh Bioscience
25 N.V., Tessenderlo, Belgium). The inter-assay imprecision (%CV) quoted by the manufacturer
26 was 2.6% for LH, 2.3% for FSH and 5.3% for testosterone. SHBG was measured according
27 to the manufacturer's instructions by chemiluminescent immunometric assay on the Immulite
28 2000 XPi analyser (Siemens Healthcare Diagnostics Ltd, Camberley, Surrey, UK). The inter-
29 assay variability (%CV) for SHBG was 5%. Calculations of free testosterone (FT) were
30 carried out using the Vermeulen equation.[15] The quoted reference ranges were: LH (2.2-
31 13.3 IU/L), FSH (1-7 IU/L), SHBG (13-71 nmol/L) and PRL (0-445 mU/L). Serum TT < 8
32 nmol/L and/or FT < 180 pmol/L was considered as biochemical hypogonadism. Serum TT 8
33 – 12 nmol/L and/or FT 180-250 pmol/L was considered as borderline/low.[18]
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **Assessment of Bone Mineral Density**

52
53 Bone mineral density was measured by DEXA scanning of the femur (neck and hip) and
54 lumbar spine or left forearm using the Lunar Prodigy DEXA (GE Lunar Corp., Madison, WI,
55
56
57
58
59
60

1
2
3 USA). Bone densitometry DEXA scans were carried out by the Department of Radiology, at
4 Corbett Hospital, Dudley, UK. Lumbar spine scan was not carried out in patients who had
5 previous spinal surgery. In those cases, assessment was performed at the left forearm site.
6
7 Results are presented as BMD (g/cm^2), T-scores and Z-scores. Reference values for T-
8
9 score were based on UK (ages 20-40) femur, spine or forearm reference population (v107).
10
11 Osteopenia was defined as a T-score between -1.0 and -2.5 SD, and osteoporosis as a T-
12
13 score at or below -2.5 SD. Measurements of height, weight and body mass index (BMI) were
14
15 also performed. The BMI scores were categorised according to the World Health
16
17 Organisation key cut-off points as <18.5 (underweight), ≥ 18.5 and ≤ 24.9 (normal weight), \geq
18
19 25 and ≤ 29.9 (overweight), and $\geq 30 \text{ kg}/\text{m}^2$ (obese). The 10-year probability of fracture was
20
21 calculated based on the Fracture Risk Assessment Tool (FRAX).[19] In addition to the BMD
22
23 value or T-score (femoral neck), this tool takes into account clinical risk factors for the
24
25 development of osteoporotic or hip fractures such as previous fractures, history of hip
26
27 fracture in the patient's parents and hypogonadism, among other factors.
28
29
30
31
32

33 **Data analysis**

34
35 Kolmogorov-Smirnov test was performed to test distribution of numerical data, followed by
36
37 the appropriate statistical tests. Comparisons between groups were carried out with the
38
39 Mann-Whitney test. Data is reported as median (minimum-maximum). The 95% confidence
40
41 intervals for the TT and FT median values were calculated for comparison with normal
42
43 reference values. Statistical significance was judged at 5% level. Statistical tests were
44
45 performed using Predictive Analytics SoftWare (PASW) (version 18.0, SPSS Inc., Chicago,
46
47 IL, USA).
48
49
50

51 **RESULTS**

52 **Assessment of Sex Hormones**

53
54
55 The median age at the time of blood collection was 58 years (47-69). The median duration
56
57
58
59
60

from implantation of the IDD system to hormone assay was 100 months (15-203) with an intrathecal opioid dose of 2.68 mg/day (range 1-9.7) (Table 1). The duration of pain prior to commencement of IDD was 9 years (range 3-35).

Table 1. Sample characteristics

Patients (N)	20
Age (years)	58 (47-69)
IDDS duration (months)	100 (15-203)
Opioid dose (mg/day)	2.68 (1-9.7)
LH (IU/L)	1.9 (0.2-19.9)
FSH (IU/L)	5.3 (0.3-23.9)
SHBG (nmol/L)	51 (17-123)
PRL (mU/L)	225 (53-614)
TT (nmol/L)	4.95 (1.2-18.8)
FT (pmol/L)	69.45 (14-328)

Key: LH - luteinizing hormone; FSH - follicle stimulating hormone; SHBG - sex hormone binding globulin; PRL - prolactin; TT – total testosterone; FT - free testosterone

Statistics are presented as median (minimum-maximum)

The median TT levels with 95% confidence intervals was 4.95 nmol/L (3.0-10.1), which were significantly lower than the cut-off level of 12 nmol/L for borderline/low testosterone. The median FT levels with 95% confidence intervals [69.45 (47.3-127.0)] were also significantly lower than the cut-off level of 180 pmol/L for low FT ($t = -3.403$, $p < 0.005$, $r = 0.61$). The mean LH, FSH and SHBG concentrations were within the respective reference ranges.

Prolactin levels were above the reference range in two patients. One of these patients had low TT and FT and the other patient presented borderline/low TT. Based on TT, 17 (85%) of the patients presented biochemical hypogonadism values with 12 (60%) at less than 8 nmol/L and 5 (25%) with TT values between 8 and 12 nmol/L (borderline/low). Based on FT calculations, 17 (85%) patients were biochemically hypogonadal with 15 (75%) at less than 180 pmol/L and two (10%) patients between 180 and 250 pmol/L. Only one of the patients had TT and FT values within quoted reference ranges, two patients presented borderline/low

1
2
3 TT and normal FT, one patient had low FT values and normal TT, and one borderline/low FT
4 and normal TT.
5
6
7

8 9 **Assessment of Bone Mineral Density**

10
11 Considering that free testosterone reflects more accurately the clinical situation than total
12 testosterone in plasma, [15] the 17 male patients diagnosed as hypogonadal through
13 calculated FT were considered for assessment of bone mineral density. Three patients were
14 excluded (one patient was excluded on the basis that the primary indication for IDD use was
15 spinal osteoporosis, one patient had the intrathecal opioid therapy discontinued and one
16 patient passed away.
17
18
19
20
21
22
23
24

25 The median age of the 14 patients at the time of BMD assessment was 62.5 years (48-70).

26
27 All the patients investigated for BMD were Caucasian. The BMI score was 29.4 kg/m² (20.1-
28 45.4). According to the BMI score, the majority of the patients (64.3%) were either
29 overweight or obese and none of the patients were underweight.
30
31
32
33
34

35 Table 2 shows the results of the BMD assessment. Individual T-scores below -1.0 SD in at
36 least one site were identified in 10 (71.4%) of the patients. Osteopenia defined as a T-score
37 between -1.0 and -2.5 SD was observed in seven (50%) of the patients. Osteoporosis
38 defined as a T-score at or below -2.5 SD was detected in three (21.4%) of the subjects.
39
40 When considering the Z-scores, one (7.1%) of the participants presented a value at or below
41 -2.5 SD indicating osteoporosis and four (28.6%) other patients Z-scores between -1.0 and -
42 2.5 SD representative of osteopenia.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Bone Mineral Density measurements

Site of measurement	BMD (g/cm ²)	T-score	Z-score
Femoral neck (n = 14)	0.925 (0.734 - 1.176)	-1.10 (-2.6 - 0.8)	-0.10 (-1.9 - 2.0)
Total hip (n = 14)	0.947 (0.686 - 1.222)	-1.10 (-3.1 - 1.0)	-0.40 (-2.6 - 1.9)
Forearm (n = 10)	0.736 (0.665 - 0.845)	-0.40 (-3.2 - 1.2)	0.30 (-2.4 - 1.7)
Lumbar (n = 4)	1.185 (0.876 - 1.487)	-0.40 (-2.4 - 2.0)	0.00 (-1.9 - 2.3)

Key: BMD - Bone Mineral Density

Statistics are presented as median (minimum-maximum)

Seven of the subjects had T-scores below -1.0 SD in more than one assessed site (Table 3).

Three patients had either osteoporosis and/or osteopenia in two sites and four patients in three sites. Three of the patients presented Z-scores lower than -1.0 SD in three sites and one patient in two sites. No statistical differences were observed between the patients within normal reference range values and those with osteopenia or osteoporosis for age ($p = 0.72$) or BMI ($p = 0.48$).

Table 3. Bone Mineral Density outcomes

Site of measurement	Normal	Osteopenia ^a	Osteoporosis ^b
Femoral neck (n = 14)	7 / 14 (50%)	5 / 14 (35.7%)	2 / 14 (14.3%)
Total hip (n = 14)	7 / 14 (50%)	4 / 14 (28.6%)	3 / 14 (21.4%)
Forearm (n = 10)	7 / 10 (70%)	2 / 10 (20%)	1 / 10 (10%)
Lumbar (n = 4)	2 / 4 (50%)	2 / 4 (50%)	

^a Osteopenia was defined as $-2.5 \text{ SD} < \text{T-score} < -1.0 \text{ SD}$

^b Osteoporosis was defined as $\text{T-score} \leq -2.5 \text{ SD}$

Values represent the number of patients/total patients (%)

Several known clinical risk factors for low bone mineral density were present in this sample including hypogonadism in all of the patients. *Investigation of osteoporosis related fractures through x-rays were not performed.* Although the patients in the studied group did not report any incident fractures, assessment of the ten-year probability of major osteoporotic or hip fracture based on the FRAX tool indicated a median probability of 5.7% (2.3-17) for major osteoporotic fracture and 1.1% (0.1-11) for hip fracture. Five (35.7%) of the patients were at or above the intervention threshold for hip fracture.

DISCUSSION

Our study showed that 85% of male patients on intrathecal opioid therapy were biochemically hypogonadal. The serum gonadotropin (LH and FSH) levels in these patients were inappropriately low or low-normal despite low serum testosterone concentrations, suggesting that testosterone suppression was caused through an inhibition of pituitary FSH and LH secretion (secondary hypogonadism). Raised serum prolactin may have contributed to the low testosterone in two patients. Although acute administration of morphine leads to an increase in PRL levels,[12] tolerance usually develops during chronic administration.[20] Previous studies investigating chronic administration of intrathecal morphine have also reported a small proportion of patients with elevated PRL levels.[17,21] In a group of cancer survivors on opioids, 90% exhibited hypogonadism and low testosterone levels; LH levels but not FSH levels were found to be significantly lower when compared with cancer survivors not on opioid therapy.[22] The important role of endogenous opioids in the control of LH secretion has been demonstrated [23] and suppression of the hypothalamic-pituitary-gonadal axis by intrathecal opioids may be caused by a similar mechanism to that of endogenous opioids.[24] Nevertheless, the suppression of LH levels may be less accentuated when the opioids are administered orally or transdermally rather than intrathecally.[12]

Several possible factors may affect the sexual function in this group of patients. Psychological aspects such as depression, passive coping strategies and catastrophising are some of the factors hypothesized to influence the sexual function in chronic pain patients.[25] However, chronic pain did not seem to be the cause of gonadal function reduction in patients undertaking intrathecal morphine therapy when compared with a control group of chronic pain patients who were not taking any form of opioid drugs.[24] Of the possible chronic illnesses identified in a longitudinal study with 890 male participants, only

1
2
3 cancer (9%) was associated with a greater decrease in testosterone levels than the
4 decrease that occurred with ageing alone.[26]
5
6
7

8
9 Hypogonadism is an important risk factor for the development of osteoporosis in both
10 sexes.[16] To our knowledge, the incidence of osteopaenia or osteoporosis in patients
11 undertaking intrathecal opioid therapy has not been previously reported. In our study, 50% of
12 patients had osteopenia and 21.4% had osteoporosis. Interestingly, an association between
13 oral opioid administration and reduced BMD was demonstrated in one study but the
14 presence or absence of hypogonadism was not assessed.[27] In a cross-sectional study,
15 osteopenia was present in 50% of the male patients undertaking oral opioids [28] but again it
16 was not clear if those patients were hypogonadal.
17
18
19
20
21
22
23
24
25
26

27 An association between oral opioid medication and an increase in fracture risk has also been
28 reported [29] but assessment of bone mineral density was not performed. The authors
29 suggested that this increase in fracture risk was possibly related to the risk of falls due to the
30 central nervous system side effect of dizziness caused by oral opioids. Opioid-induced
31 dizziness is less likely to occur in IDD patients since only a fraction of the opioid delivered
32 via intrathecal route reaches the brain. Low bone mass is an important component of the risk
33 of fracture as well as non-skeletal factors such as propensity to fall.[16,30] Many fragility
34 fractures occur in the absence of osteoporosis, although in the presence of this disease, the
35 risk of fracture is higher.[31] Osteoporotic fractures are a significant cause of morbidity and
36 mortality especially in the developed countries,[32] and are associated with increased
37 mortality, particularly in men.[33]
38
39
40
41
42
43
44
45
46
47
48
49
50

51 The assumption that hypogonadism is a risk factor for decreased BMD has not always been
52 confirmed in the literature. No association between age-related hypogonadism (based on
53 total testosterone) and decreased BMD was found in elderly men.[34] In contrast, free
54
55
56
57
58
59
60

1
2
3 testosterone (calculated according to the Vermeulen equation) was demonstrated to be an
4 independent predictor of BMD and fractures in elderly men [35] and a positive predictor of
5 cortical bone size in young men at the age of peak bone mass.[36] These contradictory
6 findings may have occurred because free testosterone is more important physiologically than
7 total testosterone. SHBG levels, which generally are genetically determined, seem to play an
8 important role in bone mass, hence the reason for free testosterone to be a stronger
9 predictor than total testosterone alone. Recently it has been suggested that SHBG levels in
10 healthy adult men at the age of peak bone mass were positively associated with cortical
11 bone size independently of sex-steroid levels.[37] However, in middle aged and elderly men,
12 SHBG elevation was significantly associated with the occurrence of osteoporotic
13 fractures.[38] Although not yet confirmed, it has been suggested that the effect of SHBG on
14 BMD may change with age and/or testosterone sufficiency or deficiency.[39]

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29 It is important to note the limitations of this study. A small number of patients were included
30 without a control group. The gonadal status and bone mineral density were not evaluated
31 prior to commencement of IDD therapy. Information on systemic opioids was not collected. A
32 proportion of these patients are provided with oral opioid medication on an individual basis
33 for occasional flare-ups. The strongest systemic opioid provided is tramadol at a dose ≤ 400
34 mg/day. Women were not included in this study. Low libido and amenorrhea have been
35 reported in female IDDS patients,[17,24] although the prevalence has been reported to be
36 lower in women.[28] A large meta-analysis, which included approximately 39,000 men and
37 women has concluded that the age-specific risk of hip fracture is similar in both men and
38 women with the same BMD and age.[40] Despite these limitations, the results of BMD
39 assessment suggest that the IDD population may have an increased risk for osteoporotic
40 fractures.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 It is important to provide appropriate treatment to patients with low BMD. FRAX analysis is a
4 simple tool that can be used to identify of patients in whom osteoporosis prophylaxis is
5 appropriate by taking into account multiple risk factors including BMD levels and
6
7 hypogonadism. BMD can be normalized and maintained within the normal range in men with
8
9 either primary or secondary hypogonadism by continuous, long-term hormonal replacement
10
11 therapy [41] though the full effect on BMD may take up to 24 months.[42] Opioid induced
12
13 hypogonadism may be reversible. Clinically significant improvements in hypogonadal
14
15 symptoms were observed in men with opioid induced androgen deficiency following
16
17 treatment with transdermal testosterone patches. [43] In patients undertaking intrathecal
18
19 opioid delivery, recovery of serum testosterone levels following cessation of therapy or
20
21 significant improvements in libido following hormonal replacement therapy have also been
22
23 reported.[17,24]
24
25
26
27

28
29 Further studies in this patient group are warranted. Future studies should prospectively
30
31 evaluate the gonadal axis, reported sexual health of the participants and BMD. It would also
32
33 be important to compare these results with matched cohorts of chronic pain patients.
34
35 Potential comparisons include patients on systemic opioids only, on a different course of
36
37 intrathecal therapy (e.g. ziconotide) or patients using spinal cord stimulation for the
38
39 management of their chronic pain.
40
41
42

43
44 This study suggests an important association between hypogonadism and low bone mass
45
46 density in patients undertaking intrathecal opioid delivery for the management of chronic
47
48 non-malignant pain. However, since the gonadal status and BMD were not determined prior
49
50 to initiation of intrathecal opioid delivery, we cannot conclude that the decreased BMD was
51
52 caused by hypogonadism or opioid administration. Early detection of hypogonadism followed
53
54 by appropriate treatment may be paramount to reduce the risk of osteoporosis development
55
56
57
58
59
60

1
2
3 and prevention of fractures in this population. Furthermore, surveillance of BMD levels in
4
5 hypogonadal intrathecal opioid delivery patients should be considered.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ARTICLE SUMMARY

Article focus

- Hypogonadism is common in intrathecal opioid therapy patients but there is limited literature investigating bone mineral density in this population.
- We aimed to prospectively investigate if undiagnosed hypogonadism in intrathecal opioid therapy patients may result in low bone mineral density levels.

Key messages

- Undiagnosed hypogonadism in intrathecal opioid therapy patients may lead to low bone mineral density levels.
- Hypogonadism and bone mineral density levels surveillance may be paramount to reduce the risk of osteoporosis and fractures in patients undertaking intrathecal opioid therapy.

Strengths and limitations of this study

- To our knowledge, this is the first study to specifically address the potential decrease in bone mineral density as a consequence of long-term intrathecal opioid therapy.
- Further studies are warranted to assess the effectiveness of early detection and adequate treatment to prevent bone mineral density decrease and to investigate the value of hormonal replacement therapy to normalise bone mineral density levels.

Acknowledgments

The authors are grateful to Dr Jane Dale from the Department of Endocrinology and Diabetes at Russells Hall Hospital for her comments on the final version of this manuscript.

Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests statement

The authors report no conflicts of interest.

Contributorship statement

RVD, JHR, JLS, MHL, AJW and RLA have made substantial contributions to (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be submitted.

Ethics approval

All assessments were performed as part of routine clinical care. No additional procedures were carried out for research purposes.

REFERENCES

- 1 Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. *Mayo Clin Proc* 1981;56:516-20.
- 2 Grady K, Raphael J. Spinal administration. In: Rice A. ed. *Textbook of Clinical Pain Management: Chronic Volume*. London: Hodder Arnold 2008:284-91.
- 3 Nordberg G, Hedner T, Mellstrand T, et al. Pharmacokinetic aspects of intrathecal morphine analgesia. *Anesthesiology* 1984;60:448-54.
- 4 Bernards C. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. *Anesthesiology* 2006;105:169-178.
- 5 Duarte RV, Raphael JH, Sparkes E, et al. Long-term intrathecal drug administration for chronic nonmalignant pain. *J Neurosurg Anesthesiol* 2012;24:63-70.
- 6 Duarte RV, Raphael JH, Haque MS, et al. A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain. *Pain Physician* 2012;15:363-69.

- 1
2
3 7 Doleys D, Dinoff B, Page L, et al. Sexual dysfunction and other side effects of intraspinal
4 opiate use in the management of chronic non-cancer pain. *American Journal of Pain*
5 *Management* 1998;8:5-11.
6
7
8
9 8 Reddy RG, Aung T, Karavitaki N, et al. Opioid induced hypogonadism. *BMJ*
10 2010;341:c4462.
11
12
13 9 Duarte RV, Raphael JH, Mourad Labib, et al. Prevalence and influence of diagnostic
14 criteria in the assessment of hypogonadism in intrathecal opioid therapy patients. *Pain*
15 *Physician* 2013;16:9-14.
16
17
18
19 10 Katz N, Mazer NA. The impact of opioids on the endocrine system. *Clin J Pain*
20 2009;25:170-5.
21
22
23 11 Petak SM, Nankin HR, Spark RF, et al. American Association of Clinical Endocrinologists
24 Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism
25 in adult male patients - 2002 update. *Endocr Pract* 2002;8:440-56.
26
27
28
29 12 Vuong C, Van Uum SHM, O'Dell LE, et al. The effects of opioids and opioid analogs on
30 animal and human endocrine systems. *Endocr Rev* 2010;31:98-132.
31
32
33 13 Schulz R, Wilhelm A, Pirke KM, et al. Beta-endorphin and dynorphin control serum
34 luteinizing hormone level in immature female rats. *Nature* 1981;294:757-9.
35
36
37 14 Pfeiffer DG, Pfeiffer A, Shimohigashi Y, et al. Predominant involvement of mu-rather than
38 delta- or kappa-opiate receptors in LH secretion. *Peptides* 1983;4:647-9.
39
40
41 15 Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the
42 estimation of free testosterone in serum. *J Clin Endocrinol Metab* 1999;84:3666-72.
43
44
45 16 Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. *Lancet*
46 2002;359:1929-36.
47
48
49 17 Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal
50 administration of opioids. *J Clin Endocrinol Metab* 2000;85:2215-22.
51
52
53 18 Hackett G, Cole NS, Deshpande AA, et al. Biochemical hypogonadism in men with type 2
54 diabetes in primary care practice. *Br J Diabetes Vasc Dis* 2009;9:226-31.
55
56
57
58
59
60

- 1
2
3 19 Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in
4 men and women from the UK. *Osteoporos Int* 2008;19:385-97.
5
6
7 20 Morley JE. The endocrinology of the opiates and opioid peptides. *Metabolism*
8 1981;30:195-209.
9
10
11 21 Paice JA, Penn RD, Ryan WG. Altered sexual function and decreased testosterone in
12 patients receiving intraspinal opioids. *J Pain Symptom Manage* 1994;9:126-31.
13
14
15 22 Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al. Symptomatic hypogonadism in
16 male survivors of cancer with chronic exposure to opioids. *Cancer* 2004;100:851-8.
17
18
19 23 Genazzani AR, Genazzani AD, Volpogni C, et al. Opioid control of gonadotrophin
20 secretion in humans. *Hum Reprod* 1993;8(Suppl 2):151-3.
21
22
23 24 Finch P, Roberts L, Price L, et al. Hypogonadism in patients treated with intrathecal
24 morphine. *Clin J Pain* 2000;16:251-4.
25
26
27 25 Monga TN, Tan G, Ostermann HJ, et al. Sexuality and sexual adjustment of patients with
28 chronic pain. *Disabil Rehabil* 1998;20:317-29.
29
30
31 26 Harman S, Metter E, Tobin J, et al. Longitudinal effects of aging on serum total and free
32 testosterone levels in healthy men. *J Clin Endocrinol Metab* 2001;86:724-31.
33
34
35 27 Kinjo M, Setoguchi S, Schneeweiss S, et al. Bone mineral density in subjects using
36 central nervous system-active medications. *Am J Med* 2005;118:1414.
37
38
39 28 Fraser LA, Morrison D, Morley-Forster P, et al. Oral opioids for chronic non-cancer pain:
40 higher prevalence of hypogonadism in men than in women. *Exp Clin Endocrinol Diabetes*
41 2009;117:38-43.
42
43
44 29 Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of
45 morphine and opiates. *J Inter Med* 2006;260:76-87.
46
47
48 30 Center JR, Nguyen TV, Sambrook PN, et al. Hormonal and biochemical parameters and
49 osteoporotic fractures in elderly men. *J Bone Miner Res* 2000;15:05-1411.
50
51
52 31 Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. *J Bone Miner*
53 Res 1994;9:1137-41.
54
55
56
57
58
59
60

- 1
2
3 32 Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated
4 with osteoporotic fractures. *Osteoporos Int* 2006;17:1726-33.
5
6
7 33 Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic
8 fracture in men and women: an observational study. *Lancet* 1999;353:878-82.
9
10
11 34 Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with
12 bone mineral density in elderly men from the Framingham study. *Ann Intern Med*
13 2000;133:951-63.
14
15
16
17 35 Mellström D, Johnell O, Ljunggren O, et al. Free testosterone is an independent predictor
18 of BMD and prevalent fractures in elderly men: MrOS Sweden. *J Bone Miner Res*
19 2006;21:529-35.
20
21
22
23 36 Lorentzon M, Swanson C, Andersson N, et al. Free testosterone is a positive, whereas
24 free estradiol is a negative, predictor of cortical bone size in young Swedish men: the
25 GOOD study. *J Bone Miner Res* 2005;20:1334-41.
26
27
28
29 37 Vanbillemont G, Lapauw B, Bogaert V, et al. Sex hormone-binding globulin as an
30 independent determinant of cortical bone status in men at the age of peak bone mass. *J*
31 *Clin Endocrinol Metab* 2010;95:1579-86.
32
33
34
35 38 Hoppé E, Bouvard B, Royer M, et al. Sex hormone-binding globulin in osteoporosis. *Joint*
36 *Bone Spine* 2010;77:306-312.
37
38
39 39 Khosla S. Sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid
40 action? *J Clin Endocrinol Metab* 2006;91:4764-6.
41
42
43
44 40 Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. *J*
45 *Bone Miner Res* 2005;20:1185-94.
46
47
48 41 Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean
49 body mass during testosterone administration in men with acquired hypogonadism. *J Clin*
50 *Endocrinol Metab* 1996;81:4358-65.
51
52
53
54 42 Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in
55 hypogonadal men. *J Clin Endocrinol Metab* 2000;85:2670-77.
56
57
58
59
60

1
2
3 43 Daniell HW, Lentz R, Mazer NA. Open-label pilot study of testosterone patch therapy in
4
5 men with opioid-induced androgen deficiency. J Pain 2006;7:200-10.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract Page 2 (b) Provide in the abstract an informative and balanced summary of what was done and what was found Page 2
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 2-4
Objectives	3	State specific objectives, including any prespecified hypotheses Page 4
Methods		
Study design	4	Present key elements of study design early in the paper Page 4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 4,5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Page 4-6 <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 4,5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 4,5
Bias	9	Describe any efforts to address potential sources of bias Page 4
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page 6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding Page 6 (b) Describe any methods used to examine subgroups and interactions Page 6 (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Continued on next page

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page 6,7 (b) Give reasons for non-participation at each stage Page 7 (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Page 6-8 (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time Page 7-9 <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Page 7 (b) Report category boundaries when continuous variables were categorized Page 5-6 (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18	Summarise key results with reference to study objectives Page 9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Page 11,12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Page 9-12
Generalisability	21	Discuss the generalisability (external validity) of the study results Page 12

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Page 13
---------	----	--

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-002856.R2
Article Type:	Research
Date Submitted by the Author:	04-May-2013
Complete List of Authors:	Duarte, Rui; Birmingham City University, Faculty of Health; Russells Hall Hospital, Department of Pain Management Raphael, Jon; Birmingham City University, Faculty of Health; Russells Hall Hospital, Department of Pain Management Southall, Jane; Russells Hall Hospital, Department of Pain Management Labib, Mourad; Russells Hall Hospital, Department of Clinical Biochemistry Whallett, Andrew; Russells Hall Hospital, Department of Rheumatology Ashford, Robert; Birmingham City University, Faculty of Health
Primary Subject Heading:	Anaesthesia
Secondary Subject Heading:	Neurology, Pharmacology and therapeutics
Keywords:	chronic pain, hypogonadism, drug delivery systems, implantable, bone density

SCHOLARONE™
Manuscripts

1
2
3 **Hypogonadism and low bone mineral density in patients on long-term intrathecal**
4 **opioid delivery therapy**

5
6 Rui V. Duarte,^{1,2} Jon H. Raphael,^{1,2} Jane L. Southall,² Mourad H. Labib,³ Andrew J.
7 Whallett,⁴ Robert L. Ashford¹

8
9 ¹ Faculty of Health, Birmingham City University, Birmingham, UK

10 ² Department of Pain Management, Russells Hall Hospital, Dudley, UK

11 ³ Department of Clinical Biochemistry, Russells Hall Hospital, Dudley, UK

12 ⁴ Department of Rheumatology, Russells Hall Hospital, Dudley, UK
13
14
15
16
17

18 Name and address for correspondence: Rui V. Duarte, Faculty of Health, Birmingham City

19 University, City South Campus, Room 220 Ravensbury House, B15 3TN, Birmingham,

20
21 United Kingdom

22
23
24 Tel.: +44 24768 88063; Fax: +44 0121 331 6076; Email: ruivduarte@gmail.com
25
26
27

28 Keywords: bone density; chronic pain; hypogonadism; drug delivery systems, implantable

29
30 Word count: 2,675
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article focus

- Hypogonadism is common in intrathecal opioid therapy patients but there is limited literature investigating bone mineral density in this population.
- We aimed to prospectively investigate if undiagnosed hypogonadism in intrathecal opioid therapy patients may result in low bone mineral density levels.

Key messages

- Undiagnosed hypogonadism in intrathecal opioid therapy patients may lead to low bone mineral density levels.
- Hypogonadism and bone mineral density levels surveillance may be paramount to reduce the risk of osteoporosis and fractures in patients undertaking intrathecal opioid therapy.

Strengths and limitations of this study

- To our knowledge, this is the first study to specifically address the potential decrease in bone mineral density as a consequence of long-term intrathecal opioid therapy.
- Further studies are warranted to assess the effectiveness of early detection and adequate treatment to prevent bone mineral density decrease and to investigate the value of hormonal replacement therapy to normalise bone mineral density levels.

ABSTRACT

Objectives

This study aimed to investigate the hypothalamic-pituitary-gonadal axis in a sample of male patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain and the presence of osteopenia and/or osteoporosis in those diagnosed with hypogonadism.

Design

Observational study using health data routinely collected for non-research purposes.

Setting

Department of Pain Management, Russells Hall Hospital, Dudley, United Kingdom.

Patients

Twenty consecutive male patients attending follow-up clinics for intrathecal opioid therapy had the gonadal axis evaluated by measuring their serum luteinising hormone, follicle stimulating hormone, total testosterone, sex hormone binding globulin and calculation of free testosterone. Bone mineral density was measured by DEXA scanning in those patients diagnosed with hypogonadism.

Results

Based on calculated free testosterone concentrations, 17 (85%) patients had biochemical hypogonadism with 15 patients (75%) having free testosterone <180 pmol/L and 2 patients (10%) between 180 and 250 pmol/L. Bone mineral density was assessed in 14 of the 17 patients after the exclusion of 3 patients. Osteoporosis (defined as a T-score \leq -2.5 SD) was detected in three patients (21.4%) and osteopenia (defined as a T-score between -1.0 and -2.5 SD) was observed in seven patients (50%). Five of the 14 patients (35.7%) were at or above the intervention threshold for hip fracture.

Conclusion

This study suggests an association between hypogonadism and low bone mass density in patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain. Surveillance of hypogonadism and bone mineral density levels followed by appropriate treatment may be paramount to reduce the risk of osteoporosis development and prevention of fractures in this group of patients.

INTRODUCTION

Treatment strategies for the management of chronic pain start with the lowest risk and least invasive intervention and progress if a treatment is not effective. Intrathecal drug delivery (IDD) is considered a last resort treatment for the management of severe chronic pain due to its invasive nature, concerns about long-term opioid use, and the possible complications related to this modality of treatment. Intrathecal spinal analgesia has become a recognized treatment for chronic non-malignant pain since the first reservoir was implanted in 1981.[1] The use of opioids via intrathecal drug delivery allows for a selective concentration to reach an important site of pain transmission, the spinal cord dorsal horn.[2] Opioid administration into the intrathecal space achieves its effects at lower doses than using the epidural route.[3] The drug is highly localized, so its analgesic efficacy is maximized at lower doses.[4]

1
2
3 Moreover, opioid dose escalation throughout the years may be modest.[5,6] These factors
4
5 lead to a decrease in the possible opioid side-effects.
6
7

8
9 The potential effect of intrathecal opioid delivery on the endocrine system is one of the least
10
11 recognised and investigated.[7] Currently, opioid-induced hypogonadism is under-
12
13 recognised and undertreated.[8,9] Some patients may attribute the signs and symptoms of
14
15 hypogonadism; such as decreased libido, tiredness, loss of muscle mass and strength,
16
17 among others, to the chronic pain and its related conditions rather than to the intrathecal
18
19 medication.[7, 10] Moreover, symptoms of hypogonadism are often neither disclosed by the
20
21 patient nor documented by the physician.[11] The current limited clinical awareness of the
22
23 opioid effects on the endocrine system, together with the lack of information on their long-
24
25 term consequences, is likely to result in a lack of information provision to the patient when
26
27 long-term opioid therapy is being considered.[12]
28
29

30
31 Animal studies suggest that opioids affect gonadotropin release via the inhibition of the
32
33 gonadotropin releasing hormone (GnRH) by β -endorphin,[13] most likely at μ -receptors.[14]
34
35 This inhibition reduces the release of luteinizing hormone (LH) and follicle stimulating
36
37 hormone (FSH) by the pituitary gland and consequently the production of testosterone by the
38
39 gonads, resulting in hypogonadism and loss of libido. This is characterized by low or low-
40
41 normal LH and FSH levels, and low testosterone levels.[11] Most circulating testosterone is
42
43 bound to sex hormone-binding globulin (SHBG). A lesser fraction is non-specifically bound to
44
45 albumin and only a small percentage of testosterone is unbound.[15] Historically, free
46
47 testosterone was thought to be the only biologically-active component. However,
48
49 testosterone is weakly bound to serum albumin and dissociates freely in the capillary bed,
50
51 and is readily available for tissue uptake. All non-SHBG-bound testosterone is therefore
52
53 considered bioavailable.
54
55
56
57
58
59
60

1
2
3 Hypogonadism is an important risk factor for development of osteoporosis in both sexes, but
4
5 opioids have not been considered as a risk factor.[16] To our knowledge, the assessment of
6
7 BMD in patients undertaking intrathecal drug delivery is limited to one study which
8
9 suggested a tendency towards decreased BMD in these patients but the prevalence of
10
11 osteopenia or osteoporosis in these patients was not reported in this study.[17]
12
13

14
15 The aim of this study was to investigate the hypothalamic-pituitary-gonadal axis in a sample
16
17 of male patients undertaking intrathecal opioid delivery for the management of chronic non-
18
19 malignant pain and to assess the prevalence of osteopenia and/or osteoporosis in those
20
21 diagnosed with hypogonadism.
22
23

24 25 **METHODS**

26 27 **Patients**

28
29 Twenty consecutive male patients attending follow-up clinics for IDD therapy at Russells Hall
30
31 Hospital, Dudley, UK, for the management of chronic non-cancer pain were included in this
32
33 observational study using health data routinely collected for non-research purposes. All
34
35 assessments were performed as part of routine clinical care. No additional procedures were
36
37 carried out for research purposes. None of these patients received testosterone
38
39 supplementation within the previous three months. The pain syndrome experienced by the
40
41 patients was classified as nociceptive (58.8%), neuropathic (5.8%) and mixed nociceptive-
42
43 neuropathic (35.3%). All the patients were receiving intrathecal opioids for the management
44
45 of their pain. Intrathecal morphine was the only medication administered to 50% of the
46
47 sample. In individual cases, other substances were added to the intrathecal medication, with
48
49 combinations of morphine with bupivacaine (12.5%), morphine with bupivacaine and
50
51 clonidine (25%), and morphine with bupivacaine and baclofen (12.5%).
52
53
54

55 56 **Laboratory Methods**

1
2
3 Blood samples were collected between 8am and 11am during a seven-month period (April to
4
5 October 2010), as part of routine clinical care, for the measurement of serum LH, FSH,
6
7 prolactin (PRL), total testosterone (TT) and SHBG. All assays were carried out by the
8
9 Department of Clinical Biochemistry at Russells Hall Hospital, Dudley, UK. LH, FSH, PRL
10
11 and TT were measured according to the manufacturer's instructions by immuno-
12
13 enzymometric fluorimetric assay on the Tosoh AIA 2000 LA analyser (Tosoh Bioscience
14
15 N.V., Tessenderlo, Belgium). The inter-assay imprecision (%CV) quoted by the manufacturer
16
17 was 2.6% for LH, 2.3% for FSH and 5.3% for testosterone. SHBG was measured according
18
19 to the manufacturer's instructions by chemiluminescent immunometric assay on the Immulite
20
21 2000 XPi analyser (Siemens Healthcare Diagnostics Ltd, Camberley, Surrey, UK). The inter-
22
23 assay variability (%CV) for SHBG was 5%. Calculations of free testosterone (FT) were
24
25 carried out using the Vermeulen equation.[15] Serum TT < 8 nmol/L and/or FT < 180 pmol/L
26
27 was considered as biochemical hypogonadism. Serum TT 8 – 12 nmol/L and/or FT 180-250
28
29 pmol/L was considered as borderline/low.[18]
30
31
32

33 **Assessment of Bone Mineral Density**

34
35 Bone mineral density was measured by DEXA scanning of the femur (neck and hip) and
36
37 lumbar spine or left forearm using the Lunar Prodigy DEXA (GE Lunar Corp., Madison, WI,
38
39 USA). Bone densitometry DEXA scans were carried out by the Department of Radiology, at
40
41 Corbett Hospital, Dudley, UK. Lumbar spine scan was not carried out in patients who had
42
43 previous spinal surgery. In those cases, assessment was performed at the left forearm site.
44
45 Results are presented as BMD (g/cm^2), T-scores and Z-scores. Reference values for T-
46
47 score were based on UK (ages 20-40) femur, spine or forearm reference population (v107).
48
49 Osteopenia was defined as a T-score between -1.0 and -2.5 SD, and osteoporosis as a T-
50
51 score at or below -2.5 SD. Measurements of height, weight and body mass index (BMI) were
52
53 also performed. The BMI scores were categorised according to the World Health
54
55 Organisation key cut-off points as <18.5 (underweight), ≥ 18.5 and ≤ 24.9 (normal weight), \geq
56
57
58
59
60

25 and ≤ 29.9 (overweight), and ≥ 30 kg/m² (obese). The 10-year probability of fracture was calculated based on the Fracture Risk Assessment Tool (FRAX).[19] In addition to the BMD value or T-score (femoral neck), this tool takes into account clinical risk factors for the development of osteoporotic or hip fractures such as previous fractures, history of hip fracture in the patient's parents and hypogonadism, among other factors.

Data analysis

Kolmogorov-Smirnov test was performed to test distribution of numerical data, followed by the appropriate statistical tests. Comparisons between groups were carried out with the Mann-Whitney test. Data is reported as median (minimum-maximum). The 95% confidence intervals for the TT and FT median values were calculated for comparison with normal reference values. Statistical significance was judged at 5% level. Statistical tests were performed using Predictive Analytics SoftWare (PASW) (version 18.0, SPSS Inc., Chicago, IL, USA).

RESULTS

Assessment of Sex Hormones

The median age at the time of blood collection was 58 years (47-69). The median duration from implantation of the IDD system to hormone assay was 100 months (15-203) with an intrathecal opioid dose of 2.68 mg/day (range 1-9.7) (Table 1). The duration of pain prior to commencement of IDD was 9 years (range 3-35).

Table 1. Reference ranges and levels in 20 men undertaking intrathecal opioid administration

	Reference range	Intrathecal opioid patients
LH (IU/L)	2.2 - 13.3	1.9 (0.2-19.9)
FSH (IU/L)	1 - 7	5.3 (0.3-23.9)
SHBG (nmol/L)	13 - 71	51 (17-123)
PRL (mU/L)	0 - 445	225 (53-614)
TT (nmol/L)	9.47 - 28.3	4.95 (1.2-18.8)

1
2
3 FT (pmol/L) 185 - 437 69.45 (14-328)

4 **Key:** LH - luteinizing hormone; FSH - follicle stimulating hormone; SHBG
5 - sex hormone binding globulin; PRL - prolactin; TT - total testosterone;
6 FT - free testosterone
7

8 Statistics are presented as median (minimum-maximum)
9

10
11 The median TT levels with 95% confidence intervals was 4.95 nmol/L (3.0-10.1), which were
12 significantly lower than the cut-off level of 12 nmol/L for borderline/low testosterone. The
13 median FT levels with 95% confidence intervals [69.45 (47.3-127.0)] were also significantly
14 lower than the cut-off level of 180 pmol/L for low FT ($t = -3.403$, $p < 0.005$, $r = 0.61$). The
15 mean LH, FSH and SHBG concentrations were within the respective reference ranges.
16
17 Prolactin levels were above the reference range in two patients. One of these patients had
18 low TT and FT and the other patient presented borderline/low TT. Based on TT, 17 (85%) of
19 the patients presented biochemical hypogonadism values with 12 (60%) at less than 8
20 nmol/L and 5 (25%) with TT values between 8 and 12 nmol/L (borderline/low). Based on FT
21 calculations, 17 (85%) patients were biochemically hypogonadal with 15 (75%) at less than
22 180 pmol/L and two (10%) patients between 180 and 250 pmol/L. Only one of the patients
23 had TT and FT values within quoted reference ranges, two patients presented borderline/low
24 TT and normal FT, one patient had low FT values and normal TT, and one borderline/low FT
25 and normal TT.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Assessment of Bone Mineral Density

Considering that free testosterone reflects more accurately the clinical situation than total testosterone in plasma, [15] the 17 male patients diagnosed as hypogonadal through calculated FT were considered for assessment of bone mineral density. Three patients were excluded (one patient was excluded on the basis that the primary indication for IDD use was spinal osteoporosis, one patient had the intrathecal opioid therapy discontinued and one patient passed away).

The median age of the 14 patients at the time of BMD assessment was 62.5 years (48-70). All the patients investigated for BMD were Caucasian. The BMI score was 29.4 kg/m² (20.1-45.4). According to the BMI score, the majority of the patients (64.3%) were either overweight or obese and none of the patients were underweight.

Table 2 shows the results of the BMD assessment. Individual T-scores below -1.0 SD in at least one site were identified in 10 (71.4%) of the patients. Osteopenia defined as a T-score between -1.0 and -2.5 SD was observed in seven (50%) of the patients. Osteoporosis defined as a T-score at or below -2.5 SD was detected in three (21.4%) of the subjects. When considering the Z-scores, one (7.1%) of the participants presented a value at or below -2.5 SD indicating osteoporosis and four (28.6%) other patients Z-scores between -1.0 and -2.5 SD representative of osteopenia.

Table 2. Bone Mineral Density measurements

Site of measurement	BMD (g/cm ²)	T-score	Z-score
Femoral neck (n = 14)	0.925 (0.734 - 1.176)	-1.10 (-2.6 - 0.8)	-0.10 (-1.9 - 2.0)
Total hip (n = 14)	0.947 (0.686 - 1.222)	-1.10 (-3.1 - 1.0)	-0.40 (-2.6 - 1.9)
Forearm (n = 10)	0.736 (0.665 - 0.845)	-0.40 (-3.2 - 1.2)	0.30 (-2.4 - 1.7)
Lumbar (n = 4)	1.185 (0.876 - 1.487)	-0.40 (-2.4 - 2.0)	0.00 (-1.9 - 2.3)

Key: BMD - Bone Mineral Density

Statistics are presented as median (minimum-maximum)

Seven of the subjects had T-scores below -1.0 SD in more than one assessed site (Table 3). Three patients had either osteoporosis and/or osteopenia in two sites and four patients in three sites. Three of the patients presented Z-scores lower than -1.0 SD in three sites and one patient in two sites. No statistical differences were observed between the patients within normal reference range values and those with osteopenia or osteoporosis for age ($p = 0.72$) or BMI ($p = 0.48$).

Table 3. Bone Mineral Density outcomes

Site of measurement	Normal	Osteopenia ^a	Osteoporosis ^b
Femoral neck (n = 14)	7 / 14 (50%)	5 / 14 (35.7%)	2 / 14 (14.3%)
Total hip (n = 14)	7 / 14 (50%)	4 / 14 (28.6%)	3 / 14 (21.4%)
Forearm (n = 10)	7 / 10 (70%)	2 / 10 (20%)	1 / 10 (10%)
Lumbar (n = 4)	2 / 4 (50%)	2 / 4 (50%)	

^a Osteopenia was defined as $-2.5 \text{ SD} < \text{T-score} < -1.0 \text{ SD}$

^b Osteoporosis was defined as $\text{T-score} \leq -2.5 \text{ SD}$

Values represent the number of patients/total patients (%)

Several known clinical risk factors for low bone mineral density were present in this sample including hypogonadism in all of the patients. Investigation of osteoporosis related fractures through x-rays were not performed. Although the patients in the studied group did not report any incident fractures, assessment of the ten-year probability of major osteoporotic or hip fracture based on the FRAX tool indicated a median probability of 5.7% (2.3-17) for major osteoporotic fracture and 1.1% (0.1-11) for hip fracture. Five (35.7%) of the patients were at or above the intervention threshold for hip fracture.

DISCUSSION

Our study showed that 85% of male patients on intrathecal opioid therapy were biochemically hypogonadal. The serum gonadotropin (LH and FSH) levels in these patients were inappropriately low or low-normal despite low serum testosterone concentrations, suggesting that testosterone suppression was caused through an inhibition of pituitary FSH and LH secretion (secondary hypogonadism). Raised serum prolactin may have contributed

1
2
3 to the low testosterone in two patients. Although acute administration of morphine leads to
4 an increase in PRL levels,[12] tolerance usually develops during chronic administration.[20]
5
6 Previous studies investigating chronic administration of intrathecal morphine have also
7
8 reported a small proportion of patients with elevated PRL levels.[17,21] In a group of cancer
9
10 survivors on opioids, 90% exhibited hypogonadism and low testosterone levels; LH levels
11
12 but not FSH levels were found to be significantly lower when compared with cancer survivors
13
14 not on opioid therapy.[22] The important role of endogenous opioids in the control of LH
15
16 secretion has been demonstrated [23] and suppression of the hypothalamic-pituitary-
17
18 gonadal axis by intrathecal opioids may be caused by a similar mechanism to that of
19
20 endogenous opioids.[24] Nevertheless, the suppression of LH levels may be less
21
22 accentuated when the opioids are administered orally or transdermally rather than
23
24 intrathecally.[12]
25
26

27
28
29 Hypogonadism is an important risk factor for the development of osteoporosis in both
30
31 sexes.[16] To our knowledge, the incidence of osteopaenia or osteoporosis in patients
32
33 undertaking intrathecal opioid therapy has not been previously reported. In our study, 50% of
34
35 patients had osteopenia and 21.4% had osteoporosis. Interestingly, an association between
36
37 oral opioid administration and reduced BMD was demonstrated in one study but the
38
39 presence or absence of hypogonadism was not assessed.[25] In a cross-sectional study,
40
41 osteopenia was present in 50% of the male patients undertaking oral opioids [26] but again it
42
43 was not clear if those patients were hypogonadal.
44
45

46
47 An association between oral opioid medication and an increase in fracture risk has also been
48
49 reported [27] but assessment of bone mineral density was not performed. The authors
50
51 suggested that this increase in fracture risk was possibly related to the risk of falls due to the
52
53 central nervous system side effect of dizziness caused by oral opioids. Opioid-induced
54
55 dizziness is less likely to occur in IDD patients since only a fraction of the opioid delivered
56
57

1
2
3 via intrathecal route reaches the brain. Low bone mass is an important component of the risk
4 of fracture as well as non-skeletal factors such as propensity to fall.[16,28] Many fragility
5 fractures occur in the absence of osteoporosis, although in the presence of this disease, the
6 risk of fracture is higher.[29] Osteoporotic fractures are a significant cause of morbidity and
7 mortality especially in the developed countries,[30] and are associated with increased
8 mortality, particularly in men.[31]

9
10
11
12
13
14
15
16
17 The assumption that hypogonadism is a risk factor for decreased BMD has not always been
18 confirmed in the literature. No association between age-related hypogonadism (based on
19 total testosterone) and decreased BMD was found in elderly men.[32] In contrast, free
20 testosterone (calculated according to the Vermeulen equation) was demonstrated to be an
21 independent predictor of BMD and fractures in elderly men [33] and a positive predictor of
22 cortical bone size in young men at the age of peak bone mass.[34] These contradictory
23 findings may have occurred because free testosterone is more important physiologically than
24 total testosterone. SHBG levels, which generally are genetically determined, seem to play an
25 important role in bone mass, hence the reason for free testosterone to be a stronger
26 predictor than total testosterone alone. Recently it has been suggested that SHBG levels in
27 healthy adult men at the age of peak bone mass were positively associated with cortical
28 bone size independently of sex-steroid levels.[35] However, in middle aged and elderly men,
29 SHBG elevation was significantly associated with the occurrence of osteoporotic
30 fractures.[36] Although not yet confirmed, it has been suggested that the effect of SHBG on
31 BMD may change with age and/or testosterone sufficiency or deficiency.[37]

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49 It is important to note the limitations of this study. A small number of patients were included
50 without a control group. The gonadal status and bone mineral density were not evaluated
51 prior to commencement of IDD therapy. Information on systemic opioids was not collected. A
52 proportion of these patients are provided with oral opioid medication on an individual basis
53
54
55
56
57
58
59
60

1
2
3 for occasional flare-ups. The strongest systemic opioid provided is tramadol at a dose \leq 400
4 mg/day. Several possible factors may affect the sexual function in this group of patients.
5
6
7 Chronic pain did not seem to be the cause of gonadal function reduction in patients
8
9 undertaking intrathecal morphine therapy when compared with a control group of chronic
10
11 pain patients who were not taking any form of opioid drugs.[24] Of the possible chronic
12
13 illnesses identified in a longitudinal study with 890 male participants, only cancer (9%) was
14
15 associated with a greater decrease in testosterone levels than the decrease that occurred
16
17 with ageing alone.[38] Women were not included in this study. Low libido and amenorrhea
18
19 have been reported in female IDDS patients,[17,24] although the prevalence has been
20
21 reported to be lower in women.[26] A large meta-analysis, which included approximately
22
23 39,000 men and women has concluded that the age-specific risk of hip fracture is similar in
24
25 both men and women with the same BMD and age.[39] Despite these limitations, the results
26
27 of BMD assessment suggest that the IDDS population may have an increased risk for
28
29 osteoporotic fractures.
30
31

32
33 It is important to provide appropriate treatment to patients with low BMD. FRAX analysis is a
34
35 simple tool that can be used to identify of patients in whom osteoporosis prophylaxis is
36
37 appropriate by taking into account multiple risk factors including BMD levels and
38
39 hypogonadism. BMD can be normalized and maintained within the normal range in men with
40
41 either primary or secondary hypogonadism by continuous, long-term hormonal replacement
42
43 therapy [40] though the full effect on BMD may take up to 24 months.[41] Opioid induced
44
45 hypogonadism may be reversible. Clinically significant improvements in hypogonadal
46
47 symptoms were observed in men with opioid induced androgen deficiency following
48
49 treatment with transdermal testosterone patches. [42] In patients undertaking intrathecal
50
51 opioid delivery, recovery of serum testosterone levels following cessation of therapy or
52
53 significant improvements in libido following hormonal replacement therapy have also been
54
55 reported.[17,24]
56
57
58
59
60

1
2
3
4
5 Further studies in this patient group are warranted. Future studies should prospectively
6
7 evaluate the gonadal axis, reported sexual health of the participants and BMD. It would also
8
9 be important to compare these results with matched cohorts of chronic pain patients.

10
11 Potential comparisons include patients on systemic opioids only, on a different course of
12
13 intrathecal therapy (e.g. ziconotide) or patients using spinal cord stimulation for the
14
15 management of their chronic pain.

16
17
18
19 This study suggests an important association between hypogonadism and low bone mass
20
21 density in patients undertaking intrathecal opioid delivery for the management of chronic
22
23 non-malignant pain. However, since the gonadal status and BMD were not determined prior
24
25 to initiation of intrathecal opioid delivery, we cannot conclude that the decreased BMD was
26
27 caused by hypogonadism or opioid administration. Early detection of hypogonadism followed
28
29 by appropriate treatment may be paramount to reduce the risk of osteoporosis development
30
31 and prevention of fractures in this population. Furthermore, surveillance of BMD levels in
32
33 hypogonadal intrathecal opioid delivery patients should be considered.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgments

The authors are grateful to Dr Jane Dale from the Department of Endocrinology and Diabetes at Russells Hall Hospital for her comments on the final version of this manuscript.

Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests statement

The authors report no conflicts of interest.

Contributorship statement

RVD, JHR, JLS, MHL, AJW and RLA have made substantial contributions to (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be submitted.

Ethics approval

All assessments were performed as part of routine clinical care. No additional procedures were carried out for research purposes.

Data sharing

No additional data available

REFERENCES

- 1 Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. *Mayo Clin Proc* 1981;56:516-20.
- 2 Grady K, Raphael J. Spinal administration. In: Rice A. ed. *Textbook of Clinical Pain Management: Chronic Volume*. London: Hodder Arnold 2008:284-91.
- 3 Nordberg G, Hedner T, Mellstrand T, et al. Pharmacokinetic aspects of intrathecal morphine analgesia. *Anesthesiology* 1984;60:448-54.
- 4 Bernards C. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. *Anesthesiology* 2006;105:169-178.
- 5 Duarte RV, Raphael JH, Sparkes E, et al. Long-term intrathecal drug administration for chronic nonmalignant pain. *J Neurosurg Anesthesiol* 2012;24:63-70.
- 6 Duarte RV, Raphael JH, Haque MS, et al. A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain. *Pain Physician* 2012;15:363-69.
- 7 Doleys D, Dinoff B, Page L, et al. Sexual dysfunction and other side effects of intraspinal opiate use in the management of chronic non-cancer pain. *American Journal of Pain Management* 1998;8:5-11.
- 8 Reddy RG, Aung T, Karavitaki N, et al. Opioid induced hypogonadism. *BMJ* 2010;341:c4462.
- 9 Duarte RV, Raphael JH, Mourad Labib, et al. Prevalence and influence of diagnostic criteria in the assessment of hypogonadism in intrathecal opioid therapy patients. *Pain Physician* 2013;16:9-14.
- 10 Katz N, Mazer NA. The impact of opioids on the endocrine system. *Clin J Pain* 2009;25:170-5.
- 11 Petak SM, Nankin HR, Spark RF, et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. *Endocr Pract* 2002;8:440-56.

- 1
2
3 12 Vuong C, Van Uum SHM, O'Dell LE, et al. The effects of opioids and opioid analogs on
4 animal and human endocrine systems. *Endocr Rev* 2010;31:98-132.
5
6
7 13 Schulz R, Wilhelm A, Pirke KM, et al. Beta-endorphin and dynorphin control serum
8 luteinizing hormone level in immature female rats. *Nature* 1981;294:757-9.
9
10
11 14 Pfeiffer DG, Pfeiffer A, Shimohigashi Y, et al. Predominant involvement of mu-rather than
12 delta- or kappa-opiate receptors in LH secretion. *Peptides* 1983;4:647-9.
13
14
15 15 Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the
16 estimation of free testosterone in serum. *J Clin Endocrinol Metab* 1999;84:3666-72.
17
18
19 16 Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. *Lancet*
20 2002;359:1929-36.
21
22
23 17 Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal
24 administration of opioids. *J Clin Endocrinol Metab* 2000;85:2215-22.
25
26
27 18 Hackett G, Cole NS, Deshpande AA, et al. Biochemical hypogonadism in men with type 2
28 diabetes in primary care practice. *Br J Diabetes Vasc Dis* 2009;9:226-31.
29
30
31 19 Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in
32 men and women from the UK. *Osteoporos Int* 2008;19:385-97.
33
34
35 20 Morley JE. The endocrinology of the opiates and opioid peptides. *Metabolism*
36 1981;30:195-209.
37
38
39 21 Paice JA, Penn RD, Ryan WG. Altered sexual function and decreased testosterone in
40 patients receiving intraspinal opioids. *J Pain Symptom Manage* 1994;9:126-31.
41
42
43 22 Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al. Symptomatic hypogonadism in
44 male survivors of cancer with chronic exposure to opioids. *Cancer* 2004;100:851-8.
45
46
47 23 Genazzani AR, Genazzani AD, Volpogni C, et al. Opioid control of gonadotrophin
48 secretion in humans. *Hum Reprod* 1993;8(Suppl 2):151-3.
49
50
51 24 Finch P, Roberts L, Price L, et al. Hypogonadism in patients treated with intrathecal
52 morphine. *Clin J Pain* 2000;16:251-4.
53
54
55
56
57
58
59
60

- 1
2
3 25 Kinjo M, Setoguchi S, Schneeweiss S, et al. Bone mineral density in subjects using
4
5 central nervous system-active medications. *Am J Med* 2005;118:1414.
6
7 26 Fraser LA, Morrison D, Morley-Forster P, et al. Oral opioids for chronic non-cancer pain:
8
9 higher prevalence of hypogonadism in men than in women. *Exp Clin Endocrinol Diabetes*
10
11 2009;117:38-43.
12
13 27 Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of
14
15 morphine and opiates. *J Inter Med* 2006;260:76-87.
16
17 28 Center JR, Nguyen TV, Sambrook PN, et al. Hormonal and biochemical parameters and
18
19 osteoporotic fractures in elderly men. *J Bone Miner Res* 2000;15:05-1411.
20
21 29 Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. *J Bone Miner*
22
23 *Res* 1994;9:1137-41.
24
25 30 Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated
26
27 with osteoporotic fractures. *Osteoporos Int* 2006;17:1726-33.
28
29 31 Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic
30
31 fracture in men and women: an observational study. *Lancet* 1999;353:878-82.
32
33 32 Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with
34
35 bone mineral density in elderly men from the Framingham study. *Ann Intern Med*
36
37 2000;133:951-63.
38
39 33 Mellström D, Johnell O, Ljunggren O, et al. Free testosterone is an independent predictor
40
41 of BMD and prevalent fractures in elderly men: MrOS Sweden. *J Bone Miner Res*
42
43 2006;21:529-35.
44
45 34 Lorentzon M, Swanson C, Andersson N, et al. Free testosterone is a positive, whereas
46
47 free estradiol is a negative, predictor of cortical bone size in young Swedish men: the
48
49 GOOD study. *J Bone Miner Res* 2005;20:1334-41.
50
51 35 Vanbillemont G, Lapauw B, Bogaert V, et al. Sex hormone-binding globulin as an
52
53 independent determinant of cortical bone status in men at the age of peak bone mass. *J*
54
55 *Clin Endocrinol Metab* 2010;95:1579-86.
56
57
58
59
60

- 1
2
3 36 Hoppé E, Bouvard B, Royer M, et al. Sex hormone-binding globulin in osteoporosis. *Joint*
4
5 Bone Spine 2010;77:306-312.
6
7 37 Khosla S. Sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid
8
9 action? *J Clin Endocrinol Metab* 2006;91:4764-6.
10
11 38 Harman S, Metter E, Tobin J, et al. Longitudinal effects of aging on serum total and free
12
13 testosterone levels in healthy men. *J Clin Endocrinol Metab* 2001;86:724-31.
14
15 39 Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. *J*
16
17 Bone Miner Res 2005;20:1185-94.
18
19 40 Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean
20
21 body mass during testosterone administration in men with acquired hypogonadism. *J Clin*
22
23 Endocrinol Metab 1996;81:4358-65.
24
25 41 Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in
26
27 hypogonadal men. *J Clin Endocrinol Metab* 2000;85:2670-77.
28
29 42 Daniell HW, Lentz R, Mazer NA. Open-label pilot study of testosterone patch therapy in
30
31 men with opioid-induced androgen deficiency. *J Pain* 2006;7:200-10.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Hypogonadism and low bone mineral density in patients on long-term intrathecal**
4 **opioid delivery therapy**

5
6 Rui V. Duarte,^{1,2} Jon H. Raphael,^{1,2} Jane L. Southall,² Mourad H. Labib,³ Andrew J.
7 Whallett,⁴ Robert L. Ashford¹

8
9 ¹ Faculty of Health, Birmingham City University, Birmingham, UK

10 ² Department of Pain Management, Russells Hall Hospital, Dudley, UK

11 ³ Department of Clinical Biochemistry, Russells Hall Hospital, Dudley, UK

12 ⁴ Department of Rheumatology, Russells Hall Hospital, Dudley, UK
13
14
15
16
17

18 Name and address for correspondence: Rui V. Duarte, Faculty of Health, Birmingham City
19 University, City South Campus, Room 220 Ravensbury House, B15 3TN, Birmingham,
20 United Kingdom
21
22

23
24 Tel.: +44 24768 88063; Fax: +44 0121 331 6076; Email: ruivduarte@gmail.com
25
26
27

28 Keywords: bone density; chronic pain; hypogonadism; drug delivery systems, implantable
29

30 Word count: 2,675
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives

This study aimed to investigate the hypothalamic-pituitary-gonadal axis in a sample of male patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain and the presence of osteopenia and/or osteoporosis in those diagnosed with hypogonadism.

Design

Observational study using health data routinely collected for non-research purposes.

Setting

Department of Pain Management, Russells Hall Hospital, Dudley, United Kingdom.

Patients

Twenty consecutive male patients attending follow-up clinics for intrathecal opioid therapy had the gonadal axis evaluated by measuring their serum luteinising hormone, follicle stimulating hormone, total testosterone, sex hormone binding globulin and calculation of free testosterone. Bone mineral density was measured by DEXA scanning in those patients diagnosed with hypogonadism.

Results

Based on calculated free testosterone concentrations, 17 (85%) patients had biochemical hypogonadism with 15 patients (75%) having free testosterone <180 pmol/L and 2 patients (10%) between 180 and 250 pmol/L. Bone mineral density was assessed in 14 of the 17 patients after the exclusion of 3 patients. Osteoporosis (defined as a T-score \leq -2.5 SD) was detected in three patients (21.4%) and osteopenia (defined as a T-score between -1.0 and -2.5 SD) was observed in seven patients (50%). Five of the 14 patients (35.7%) were at or above the intervention threshold for hip fracture.

Conclusion

This study suggests an association between hypogonadism and low bone mass density in patients undertaking intrathecal opioid delivery for the management of chronic non-malignant pain. Surveillance of hypogonadism and bone mineral density levels followed by appropriate treatment may be paramount to reduce the risk of osteoporosis development and prevention of fractures in this group of patients.

INTRODUCTION

Treatment strategies for the management of chronic pain start with the lowest risk and least invasive intervention and progress if a treatment is not effective. Intrathecal drug delivery

1
2
3 (IDD) is considered a last resort treatment for the management of severe chronic pain due to
4 its invasive nature, concerns about long-term opioid use, and the possible complications
5 related to this modality of treatment. Intrathecal spinal analgesia has become a recognized
6 treatment for chronic non-malignant pain since the first reservoir was implanted in 1981.[1]
7
8 The use of opioids via intrathecal drug delivery allows for a selective concentration to reach
9 an important site of pain transmission, the spinal cord dorsal horn.[2] Opioid administration
10 into the intrathecal space achieves its effects at lower doses than using the epidural route.[3]
11
12 The drug is highly localized, so its analgesic efficacy is maximized at lower doses.[4]
13
14 Moreover, opioid dose escalation throughout the years may be modest.[5,6] These factors
15 lead to a decrease in the possible opioid side-effects.
16
17
18
19
20
21
22
23
24

25 The potential effect of intrathecal opioid delivery on the endocrine system is one of the least
26 recognised and investigated.[7] Currently, opioid-induced hypogonadism is under-
27 recognised and undertreated.[8,9] Some patients may attribute the signs and symptoms of
28 hypogonadism; such as decreased libido, tiredness, loss of muscle mass and strength,
29 among others, to the chronic pain and its related conditions rather than to the intrathecal
30 medication.[7, 10] Moreover, symptoms of hypogonadism are often neither disclosed by the
31 patient nor documented by the physician.[11] The current limited clinical awareness of the
32 opioid effects on the endocrine system, together with the lack of information on their long-
33 term consequences, is likely to result in a lack of information provision to the patient when
34 long-term opioid therapy is being considered.[12]
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Animal studies suggest that opioids affect gonadotropin release via the inhibition of the
49 gonadotropin releasing hormone (GnRH) by β -endorphin,[13] most likely at μ -receptors.[14]
50 This inhibition reduces the release of luteinizing hormone (LH) and follicle stimulating
51 hormone (FSH) by the pituitary gland and consequently the production of testosterone by the
52 gonads, resulting in hypogonadism and loss of libido. This is characterized by low or low-
53
54
55
56
57
58
59
60

1
2
3 normal LH and FSH levels, and low testosterone levels.[11] Most circulating testosterone is
4 bound to sex hormone-binding globulin (SHBG). A lesser fraction is non-specifically bound to
5 albumin and only a small percentage of testosterone is unbound.[15] Historically, free
6 testosterone was thought to be the only biologically-active component. However,
7 testosterone is weakly bound to serum albumin and dissociates freely in the capillary bed,
8 and is readily available for tissue uptake. All non-SHBG-bound testosterone is therefore
9 considered bioavailable.
10
11
12
13
14
15
16
17
18

19 Hypogonadism is an important risk factor for development of osteoporosis in both sexes, but
20 opioids have not been considered as a risk factor.[16] To our knowledge, the assessment of
21 BMD in patients undertaking intrathecal drug delivery is limited to one study which
22 suggested a tendency towards decreased BMD in these patients but the prevalence of
23 osteopenia or osteoporosis in these patients was not reported in this study.[17]
24
25
26
27
28
29
30

31 The aim of this study was to investigate the hypothalamic-pituitary-gonadal axis in a sample
32 of male patients undertaking intrathecal opioid delivery for the management of chronic non-
33 malignant pain and to assess the prevalence of osteopenia and/or osteoporosis in those
34 diagnosed with hypogonadism.
35
36
37
38
39
40

41 **METHODS**

42 **Patients**

43
44 Twenty consecutive male patients attending follow-up clinics for IDD therapy at Russells Hall
45 Hospital, Dudley, UK, for the management of chronic non-cancer pain were included in this
46 observational study using health data routinely collected for non-research purposes. All
47 assessments were performed as part of routine clinical care. No additional procedures were
48 carried out for research purposes. None of these patients received testosterone
49 supplementation within the previous three months. The pain syndrome experienced by the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 patients was classified as nociceptive (58.8%), neuropathic (5.8%) and mixed nociceptive-
4
5 neuropathic (35.3%). All the patients were receiving intrathecal opioids for the management
6
7 of their pain. Intrathecal morphine was the only medication administered to 50% of the
8
9 sample. In individual cases, other substances were added to the intrathecal medication, with
10
11 combinations of morphine with bupivacaine (12.5%), morphine with bupivacaine and
12
13 clonidine (25%), and morphine with bupivacaine and baclofen (12.5%).
14

15 16 17 **Laboratory Methods**

18
19 Blood samples were collected between 8am and 11am during a seven-month period (April to
20
21 October 2010), as part of routine clinical care, for the measurement of serum LH, FSH,
22
23 prolactin (PRL), total testosterone (TT) and SHBG. All assays were carried out by the
24
25 Department of Clinical Biochemistry at Russells Hall Hospital, Dudley, UK. LH, FSH, PRL
26
27 and TT were measured according to the manufacturer's instructions by immuno-
28
29 enzymometric fluorimetric assay on the Tosoh AIA 2000 LA analyser (Tosoh Bioscience
30
31 N.V., Tessenderlo, Belgium). The inter-assay imprecision (%CV) quoted by the manufacturer
32
33 was 2.6% for LH, 2.3% for FSH and 5.3% for testosterone. SHBG was measured according
34
35 to the manufacturer's instructions by chemiluminescent immunometric assay on the Immulite
36
37 2000 XPi analyser (Siemens Healthcare Diagnostics Ltd, Camberley, Surrey, UK). The inter-
38
39 assay variability (%CV) for SHBG was 5%. Calculations of free testosterone (FT) were
40
41 carried out using the Vermeulen equation.[15] Serum TT < 8 nmol/L and/or FT < 180 pmol/L
42
43 was considered as biochemical hypogonadism. Serum TT 8 – 12 nmol/L and/or FT 180-250
44
45 pmol/L was considered as borderline/low.[18]
46
47
48

49 50 **Assessment of Bone Mineral Density**

51
52 Bone mineral density was measured by DEXA scanning of the femur (neck and hip) and
53
54 lumbar spine or left forearm using the Lunar Prodigy DEXA (GE Lunar Corp., Madison, WI,
55
56 USA). Bone densitometry DEXA scans were carried out by the Department of Radiology, at
57
58
59
60

1
2
3 Corbett Hospital, Dudley, UK. Lumbar spine scan was not carried out in patients who had
4 previous spinal surgery. In those cases, assessment was performed at the left forearm site.
5 Results are presented as BMD (g/cm^2), T-scores and Z-scores. Reference values for T-
6 score were based on UK (ages 20-40) femur, spine or forearm reference population (v107).
7 Osteopenia was defined as a T-score between -1.0 and -2.5 SD, and osteoporosis as a T-
8 score at or below -2.5 SD. Measurements of height, weight and body mass index (BMI) were
9 also performed. The BMI scores were categorised according to the World Health
10 Organisation key cut-off points as <18.5 (underweight), ≥ 18.5 and ≤ 24.9 (normal weight), \geq
11 25 and ≤ 29.9 (overweight), and $\geq 30 \text{ kg}/\text{m}^2$ (obese). The 10-year probability of fracture was
12 calculated based on the Fracture Risk Assessment Tool (FRAX).[19] In addition to the BMD
13 value or T-score (femoral neck), this tool takes into account clinical risk factors for the
14 development of osteoporotic or hip fractures such as previous fractures, history of hip
15 fracture in the patient's parents and hypogonadism, among other factors.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **Data analysis**

32 Kolmogorov-Smirnov test was performed to test distribution of numerical data, followed by
33 the appropriate statistical tests. Comparisons between groups were carried out with the
34 Mann-Whitney test. Data is reported as median (minimum-maximum). The 95% confidence
35 intervals for the TT and FT median values were calculated for comparison with normal
36 reference values. Statistical significance was judged at 5% level. Statistical tests were
37 performed using Predictive Analytics SoftWare (PASW) (version 18.0, SPSS Inc., Chicago,
38 IL, USA).
39
40
41
42
43
44
45
46
47
48

49 **RESULTS**

50 **Assessment of Sex Hormones**

51 The median age at the time of blood collection was 58 years (47-69). The median duration
52 from implantation of the IDD system to hormone assay was 100 months (15-203) with an
53
54
55
56
57
58
59
60

intrathecal opioid dose of 2.68 mg/day (range 1-9.7) (Table 1). The duration of pain prior to commencement of IDD was 9 years (range 3-35).

Table 1. Reference ranges and levels in 20 men undertaking intrathecal opioid administration

	Reference range	Intrathecal opioid patients
LH (IU/L)	2.2 - 13.3	1.9 (0.2-19.9)
FSH (IU/L)	1 - 7	5.3 (0.3-23.9)
SHBG (nmol/L)	13 - 71	51 (17-123)
PRL (mU/L)	0 - 445	225 (53-614)
TT (nmol/L)	9.47 - 28.3	4.95 (1.2-18.8)
FT (pmol/L)	185 - 437	69.45 (14-328)

Key: LH - luteinizing hormone; FSH - follicle stimulating hormone; SHBG - sex hormone binding globulin; PRL - prolactin; TT - total testosterone; FT - free testosterone

Statistics are presented as median (minimum-maximum)

The median TT levels with 95% confidence intervals was 4.95 nmol/L (3.0-10.1), which were significantly lower than the cut-off level of 12 nmol/L for borderline/low testosterone. The median FT levels with 95% confidence intervals [69.45 (47.3-127.0)] were also significantly lower than the cut-off level of 180 pmol/L for low FT ($t = -3.403$, $p < 0.005$, $r = 0.61$). The mean LH, FSH and SHBG concentrations were within the respective reference ranges.

Prolactin levels were above the reference range in two patients. One of these patients had low TT and FT and the other patient presented borderline/low TT. Based on TT, 17 (85%) of the patients presented biochemical hypogonadism values with 12 (60%) at less than 8 nmol/L and 5 (25%) with TT values between 8 and 12 nmol/L (borderline/low). Based on FT calculations, 17 (85%) patients were biochemically hypogonadal with 15 (75%) at less than 180 pmol/L and two (10%) patients between 180 and 250 pmol/L. Only one of the patients had TT and FT values within quoted reference ranges, two patients presented borderline/low TT and normal FT, one patient had low FT values and normal TT, and one borderline/low FT and normal TT.

Assessment of Bone Mineral Density

Considering that free testosterone reflects more accurately the clinical situation than total testosterone in plasma, [15] the 17 male patients diagnosed as hypogonadal through calculated FT were considered for assessment of bone mineral density. Three patients were excluded (one patient was excluded on the basis that the primary indication for IDD use was spinal osteoporosis, one patient had the intrathecal opioid therapy discontinued and one patient passed away).

The median age of the 14 patients at the time of BMD assessment was 62.5 years (48-70). All the patients investigated for BMD were Caucasian. The BMI score was 29.4 kg/m² (20.1-45.4). According to the BMI score, the majority of the patients (64.3%) were either overweight or obese and none of the patients were underweight.

Table 2 shows the results of the BMD assessment. Individual T-scores below -1.0 SD in at least one site were identified in 10 (71.4%) of the patients. Osteopenia defined as a T-score between -1.0 and -2.5 SD was observed in seven (50%) of the patients. Osteoporosis defined as a T-score at or below -2.5 SD was detected in three (21.4%) of the subjects. When considering the Z-scores, one (7.1%) of the participants presented a value at or below -2.5 SD indicating osteoporosis and four (28.6%) other patients Z-scores between -1.0 and -2.5 SD representative of osteopenia.

Table 2. Bone Mineral Density measurements

Site of measurement	BMD (g/cm ²)	T-score	Z-score
Femoral neck (n = 14)	0.925 (0.734 - 1.176)	-1.10 (-2.6 - 0.8)	-0.10 (-1.9 - 2.0)
Total hip (n = 14)	0.947 (0.686 - 1.222)	-1.10 (-3.1 - 1.0)	-0.40 (-2.6 - 1.9)
Forearm (n = 10)	0.736 (0.665 - 0.845)	-0.40 (-3.2 - 1.2)	0.30 (-2.4 - 1.7)
Lumbar (n = 4)	1.185 (0.876 - 1.487)	-0.40 (-2.4 - 2.0)	0.00 (-1.9 - 2.3)

Key: BMD - Bone Mineral Density

Statistics are presented as median (minimum-maximum)

Seven of the subjects had T-scores below -1.0 SD in more than one assessed site (Table 3). Three patients had either osteoporosis and/or osteopenia in two sites and four patients in three sites. Three of the patients presented Z-scores lower than -1.0 SD in three sites and one patient in two sites. No statistical differences were observed between the patients within normal reference range values and those with osteopenia or osteoporosis for age ($p = 0.72$) or BMI ($p = 0.48$).

Table 3. Bone Mineral Density outcomes

Site of measurement	Normal	Osteopenia ^a	Osteoporosis ^b
Femoral neck (n = 14)	7 / 14 (50%)	5 / 14 (35.7%)	2 / 14 (14.3%)
Total hip (n = 14)	7 / 14 (50%)	4 / 14 (28.6%)	3 / 14 (21.4%)
Forearm (n = 10)	7 / 10 (70%)	2 / 10 (20%)	1 / 10 (10%)
Lumbar (n = 4)	2 / 4 (50%)	2 / 4 (50%)	

^a Osteopenia was defined as $-2.5 \text{ SD} < \text{T-score} < -1.0 \text{ SD}$

^b Osteoporosis was defined as $\text{T-score} \leq -2.5 \text{ SD}$

Values represent the number of patients/total patients (%)

Several known clinical risk factors for low bone mineral density were present in this sample including hypogonadism in all of the patients. *Investigation of osteoporosis related fractures through x-rays were not performed.* Although the patients in the studied group did not report any incident fractures, assessment of the ten-year probability of major osteoporotic or hip fracture based on the FRAX tool indicated a median probability of 5.7% (2.3-17) for major osteoporotic fracture and 1.1% (0.1-11) for hip fracture. Five (35.7%) of the patients were at or above the intervention threshold for hip fracture.

DISCUSSION

Our study showed that 85% of male patients on intrathecal opioid therapy were biochemically hypogonadal. The serum gonadotropin (LH and FSH) levels in these patients were inappropriately low or low-normal despite low serum testosterone concentrations, suggesting that testosterone suppression was caused through an inhibition of pituitary FSH and LH secretion (secondary hypogonadism). *Raised serum prolactin may have contributed*

1
2
3 to the low testosterone in two patients. Although acute administration of morphine leads to
4 an increase in PRL levels,[12] tolerance usually develops during chronic administration.[20]
5
6 Previous studies investigating chronic administration of intrathecal morphine have also
7
8 reported a small proportion of patients with elevated PRL levels.[17,21] In a group of cancer
9
10 survivors on opioids, 90% exhibited hypogonadism and low testosterone levels; LH levels
11
12 but not FSH levels were found to be significantly lower when compared with cancer survivors
13
14 not on opioid therapy.[22] The important role of endogenous opioids in the control of LH
15
16 secretion has been demonstrated [23] and suppression of the hypothalamic-pituitary-
17
18 gonadal axis by intrathecal opioids may be caused by a similar mechanism to that of
19
20 endogenous opioids.[24] Nevertheless, the suppression of LH levels may be less
21
22 accentuated when the opioids are administered orally or transdermally rather than
23
24 intrathecally.[12]
25
26
27
28

29 Hypogonadism is an important risk factor for the development of osteoporosis in both
30
31 sexes.[16] To our knowledge, the incidence of osteopaenia or osteoporosis in patients
32
33 undertaking intrathecal opioid therapy has not been previously reported. In our study, 50% of
34
35 patients had osteopenia and 21.4% had osteoporosis. Interestingly, an association between
36
37 oral opioid administration and reduced BMD was demonstrated in one study but the
38
39 presence or absence of hypogonadism was not assessed.[25] In a cross-sectional study,
40
41 osteopenia was present in 50% of the male patients undertaking oral opioids [26] but again it
42
43 was not clear if those patients were hypogonadal.
44
45
46
47

48 An association between oral opioid medication and an increase in fracture risk has also been
49
50 reported [27] but assessment of bone mineral density was not performed. The authors
51
52 suggested that this increase in fracture risk was possibly related to the risk of falls due to the
53
54 central nervous system side effect of dizziness caused by oral opioids. Opioid-induced
55
56 dizziness is less likely to occur in IDD patients since only a fraction of the opioid delivered
57
58
59
60

1
2
3 via intrathecal route reaches the brain. Low bone mass is an important component of the risk
4 of fracture as well as non-skeletal factors such as propensity to fall.[16,28] Many fragility
5 fractures occur in the absence of osteoporosis, although in the presence of this disease, the
6 risk of fracture is higher.[29] Osteoporotic fractures are a significant cause of morbidity and
7 mortality especially in the developed countries,[30] and are associated with increased
8 mortality, particularly in men.[31]

9
10
11
12
13
14
15
16
17 The assumption that hypogonadism is a risk factor for decreased BMD has not always been
18 confirmed in the literature. No association between age-related hypogonadism (based on
19 total testosterone) and decreased BMD was found in elderly men.[32] In contrast, free
20 testosterone (calculated according to the Vermeulen equation) was demonstrated to be an
21 independent predictor of BMD and fractures in elderly men [33] and a positive predictor of
22 cortical bone size in young men at the age of peak bone mass.[34] These contradictory
23 findings may have occurred because free testosterone is more important physiologically than
24 total testosterone. SHBG levels, which generally are genetically determined, seem to play an
25 important role in bone mass, hence the reason for free testosterone to be a stronger
26 predictor than total testosterone alone. Recently it has been suggested that SHBG levels in
27 healthy adult men at the age of peak bone mass were positively associated with cortical
28 bone size independently of sex-steroid levels.[35] However, in middle aged and elderly men,
29 SHBG elevation was significantly associated with the occurrence of osteoporotic
30 fractures.[36] Although not yet confirmed, it has been suggested that the effect of SHBG on
31 BMD may change with age and/or testosterone sufficiency or deficiency.[37]

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49 It is important to note the limitations of this study. A small number of patients were included
50 without a control group. The gonadal status and bone mineral density were not evaluated
51 prior to commencement of IDD therapy. Information on systemic opioids was not collected. A
52 proportion of these patients are provided with oral opioid medication on an individual basis
53
54
55
56
57
58
59
60

1
2
3 for occasional flare-ups. The strongest systemic opioid provided is tramadol at a dose ≤ 400
4 mg/day. Several possible factors may affect the sexual function in this group of patients.
5
6
7 Chronic pain did not seem to be the cause of gonadal function reduction in patients
8
9 undertaking intrathecal morphine therapy when compared with a control group of chronic
10
11 pain patients who were not taking any form of opioid drugs.[24] Of the possible chronic
12
13 illnesses identified in a longitudinal study with 890 male participants, only cancer (9%) was
14
15 associated with a greater decrease in testosterone levels than the decrease that occurred
16
17 with ageing alone.[38] Women were not included in this study. Low libido and amenorrhea
18
19 have been reported in female IDDS patients,[17,24] although the prevalence has been
20
21 reported to be lower in women.[26] A large meta-analysis, which included approximately
22
23 39,000 men and women has concluded that the age-specific risk of hip fracture is similar in
24
25 both men and women with the same BMD and age.[39] Despite these limitations, the results
26
27 of BMD assessment suggest that the IDDS population may have an increased risk for
28
29 osteoporotic fractures.
30
31

32
33 It is important to provide appropriate treatment to patients with low BMD. FRAX analysis is a
34
35 simple tool that can be used to identify of patients in whom osteoporosis prophylaxis is
36
37 appropriate by taking into account multiple risk factors including BMD levels and
38
39 hypogonadism. BMD can be normalized and maintained within the normal range in men with
40
41 either primary or secondary hypogonadism by continuous, long-term hormonal replacement
42
43 therapy [40] though the full effect on BMD may take up to 24 months.[41] Opioid induced
44
45 hypogonadism may be reversible. Clinically significant improvements in hypogonadal
46
47 symptoms were observed in men with opioid induced androgen deficiency following
48
49 treatment with transdermal testosterone patches. [42] In patients undertaking intrathecal
50
51 opioid delivery, recovery of serum testosterone levels following cessation of therapy or
52
53 significant improvements in libido following hormonal replacement therapy have also been
54
55 reported.[17,24]
56
57
58
59
60

1
2
3
4
5 Further studies in this patient group are warranted. Future studies should prospectively
6
7 evaluate the gonadal axis, reported sexual health of the participants and BMD. It would also
8
9 be important to compare these results with matched cohorts of chronic pain patients.

10
11 Potential comparisons include patients on systemic opioids only, on a different course of
12
13 intrathecal therapy (e.g. ziconotide) or patients using spinal cord stimulation for the
14
15 management of their chronic pain.

16
17
18
19 This study suggests an important association between hypogonadism and low bone mass
20
21 density in patients undertaking intrathecal opioid delivery for the management of chronic
22
23 non-malignant pain. However, since the gonadal status and BMD were not determined prior
24
25 to initiation of intrathecal opioid delivery, we cannot conclude that the decreased BMD was
26
27 caused by hypogonadism or opioid administration. Early detection of hypogonadism followed
28
29 by appropriate treatment may be paramount to reduce the risk of osteoporosis development
30
31 and prevention of fractures in this population. Furthermore, surveillance of BMD levels in
32
33 hypogonadal intrathecal opioid delivery patients should be considered.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article focus

- Hypogonadism is common in intrathecal opioid therapy patients but there is limited literature investigating bone mineral density in this population.
- We aimed to prospectively investigate if undiagnosed hypogonadism in intrathecal opioid therapy patients may result in low bone mineral density levels.

Key messages

- Undiagnosed hypogonadism in intrathecal opioid therapy patients may lead to low bone mineral density levels.
- Hypogonadism and bone mineral density levels surveillance may be paramount to reduce the risk of osteoporosis and fractures in patients undertaking intrathecal opioid therapy.

Strengths and limitations of this study

- To our knowledge, this is the first study to specifically address the potential decrease in bone mineral density as a consequence of long-term intrathecal opioid therapy.
- Further studies are warranted to assess the effectiveness of early detection and adequate treatment to prevent bone mineral density decrease and to investigate the value of hormonal replacement therapy to normalise bone mineral density levels.

Acknowledgments

The authors are grateful to Dr Jane Dale from the Department of Endocrinology and Diabetes at Russells Hall Hospital for her comments on the final version of this manuscript.

Funding statement

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests statement

The authors report no conflicts of interest.

Contributorship statement

RVD, JHR, JLS, MHL, AJW and RLA have made substantial contributions to (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be submitted.

Ethics approval

All assessments were performed as part of routine clinical care. No additional procedures were carried out for research purposes.

REFERENCES

- 1 Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. *Mayo Clin Proc* 1981;56:516-20.
- 2 Grady K, Raphael J. Spinal administration. In: Rice A. ed. *Textbook of Clinical Pain Management: Chronic Volume*. London: Hodder Arnold 2008:284-91.
- 3 Nordberg G, Hedner T, Mellstrand T, et al. Pharmacokinetic aspects of intrathecal morphine analgesia. *Anesthesiology* 1984;60:448-54.
- 4 Bernards C. Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. *Anesthesiology* 2006;105:169-178.
- 5 Duarte RV, Raphael JH, Sparkes E, et al. Long-term intrathecal drug administration for chronic nonmalignant pain. *J Neurosurg Anesthesiol* 2012;24:63-70.
- 6 Duarte RV, Raphael JH, Haque MS, et al. A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain. *Pain Physician* 2012;15:363-69.

- 1
2
3 7 Doleys D, Dinoff B, Page L, et al. Sexual dysfunction and other side effects of intraspinal
4 opiate use in the management of chronic non-cancer pain. *American Journal of Pain*
5 Management 1998;8:5-11.
6
7
8
9 8 Reddy RG, Aung T, Karavitaki N, et al. Opioid induced hypogonadism. *BMJ*
10 2010;341:c4462.
11
12
13 9 Duarte RV, Raphael JH, Mourad Labib, et al. Prevalence and influence of diagnostic
14 criteria in the assessment of hypogonadism in intrathecal opioid therapy patients. *Pain*
15 Physician 2013;16:9-14.
16
17
18
19 10 Katz N, Mazer NA. The impact of opioids on the endocrine system. *Clin J Pain*
20 2009;25:170-5.
21
22
23 11 Petak SM, Nankin HR, Spark RF, et al. American Association of Clinical Endocrinologists
24 Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism
25 in adult male patients - 2002 update. *Endocr Pract* 2002;8:440-56.
26
27
28
29 12 Vuong C, Van Uum SHM, O'Dell LE, et al. The effects of opioids and opioid analogs on
30 animal and human endocrine systems. *Endocr Rev* 2010;31:98-132.
31
32
33 13 Schulz R, Wilhelm A, Pirke KM, et al. Beta-endorphin and dynorphin control serum
34 luteinizing hormone level in immature female rats. *Nature* 1981;294:757-9.
35
36
37 14 Pfeiffer DG, Pfeiffer A, Shimohigashi Y, et al. Predominant involvement of mu-rather than
38 delta- or kappa-opiate receptors in LH secretion. *Peptides* 1983;4:647-9.
39
40
41 15 Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the
42 estimation of free testosterone in serum. *J Clin Endocrinol Metab* 1999;84:3666-72.
43
44
45 16 Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. *Lancet*
46 2002;359:1929-36.
47
48
49 17 Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal
50 administration of opioids. *J Clin Endocrinol Metab* 2000;85:2215-22.
51
52
53 18 Hackett G, Cole NS, Deshpande AA, et al. Biochemical hypogonadism in men with type 2
54 diabetes in primary care practice. *Br J Diabetes Vasc Dis* 2009;9:226-31.
55
56
57
58
59
60

- 1
2
3 19 Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in
4 men and women from the UK. *Osteoporos Int* 2008;19:385-97.
5
6
7 20 Morley JE. The endocrinology of the opiates and opioid peptides. *Metabolism*
8 1981;30:195-209.
9
10
11 21 Paice JA, Penn RD, Ryan WG. Altered sexual function and decreased testosterone in
12 patients receiving intraspinal opioids. *J Pain Symptom Manage* 1994;9:126-31.
13
14 22 Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al. Symptomatic hypogonadism in
15 male survivors of cancer with chronic exposure to opioids. *Cancer* 2004;100:851-8.
16
17 23 Genazzani AR, Genazzani AD, Volpogni C, et al. Opioid control of gonadotrophin
18 secretion in humans. *Hum Reprod* 1993;8(Suppl 2):151-3.
19
20 24 Finch P, Roberts L, Price L, et al. Hypogonadism in patients treated with intrathecal
21 morphine. *Clin J Pain* 2000;16:251-4.
22
23 25 Kinjo M, Setoguchi S, Schneeweiss S, et al. Bone mineral density in subjects using
24 central nervous system-active medications. *Am J Med* 2005;118:1414.
25
26 26 Fraser LA, Morrison D, Morley-Forster P, et al. Oral opioids for chronic non-cancer pain:
27 higher prevalence of hypogonadism in men than in women. *Exp Clin Endocrinol Diabetes*
28 2009;117:38-43.
29
30 27 Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of
31 morphine and opiates. *J Inter Med* 2006;260:76-87.
32
33 28 Center JR, Nguyen TV, Sambrook PN, et al. Hormonal and biochemical parameters and
34 osteoporotic fractures in elderly men. *J Bone Miner Res* 2000;15:05-1411.
35
36 29 Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. *J Bone Miner*
37 *Res* 1994;9:1137-41.
38
39 30 Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated
40 with osteoporotic fractures. *Osteoporos Int* 2006;17:1726-33.
41
42 31 Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic
43 fracture in men and women: an observational study. *Lancet* 1999;353:878-82.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 32 Amin S, Zhang Y, Sawin CT, et al. Association of hypogonadism and estradiol levels with
4 bone mineral density in elderly men from the Framingham study. *Ann Intern Med*
5 2000;133:951-63.
6
7
8
9 33 Mellström D, Johnell O, Ljunggren O, et al. Free testosterone is an independent predictor
10 of BMD and prevalent fractures in elderly men: MrOS Sweden. *J Bone Miner Res*
11 2006;21:529-35.
12
13
14 34 Lorentzon M, Swanson C, Andersson N, et al. Free testosterone is a positive, whereas
15 free estradiol is a negative, predictor of cortical bone size in young Swedish men: the
16 GOOD study. *J Bone Miner Res* 2005;20:1334-41.
17
18
19
20 35 Vanbillemont G, Lapauw B, Bogaert V, et al. Sex hormone-binding globulin as an
21 independent determinant of cortical bone status in men at the age of peak bone mass. *J*
22 *Clin Endocrinol Metab* 2010;95:1579-86.
23
24
25
26 36 Hoppé E, Bouvard B, Royer M, et al. Sex hormone-binding globulin in osteoporosis. *Joint*
27 *Bone Spine* 2010;77:306-312.
28
29
30
31 37 Khosla S. Sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid
32 action? *J Clin Endocrinol Metab* 2006;91:4764-6.
33
34
35
36 38 Harman S, Metter E, Tobin J, et al. Longitudinal effects of aging on serum total and free
37 testosterone levels in healthy men. *J Clin Endocrinol Metab* 2001;86:724-31.
38
39
40 39 Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. *J*
41 *Bone Miner Res* 2005;20:1185-94.
42
43
44 40 Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean
45 body mass during testosterone administration in men with acquired hypogonadism. *J Clin*
46 *Endocrinol Metab* 1996;81:4358-65.
47
48
49
50 41 Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in
51 hypogonadal men. *J Clin Endocrinol Metab* 2000;85:2670-77.
52
53
54 42 Daniell HW, Lentz R, Mazer NA. Open-label pilot study of testosterone patch therapy in
55 men with opioid-induced androgen deficiency. *J Pain* 2006;7:200-10.
56
57
58
59
60

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract Page 2 (b) Provide in the abstract an informative and balanced summary of what was done and what was found Page 2
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 2-4
Objectives	3	State specific objectives, including any prespecified hypotheses Page 4
Methods		
Study design	4	Present key elements of study design early in the paper Page 4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 4,5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Page 4-6 <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 4,5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 4,5
Bias	9	Describe any efforts to address potential sources of bias Page 4
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page 6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding Page 6 (b) Describe any methods used to examine subgroups and interactions Page 6 (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Continued on next page

Results

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page 6,7 (b) Give reasons for non-participation at each stage Page 7 (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Page 6-8 (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time Page 7-9 <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Page 7 (b) Report category boundaries when continuous variables were categorized Page 5-6 (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Key results	18	Summarise key results with reference to study objectives Page 9
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Page 11,12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Page 9-12
Generalisability	21	Discuss the generalisability (external validity) of the study results Page 12

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Page 13
---------	----	--

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.